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ABSTRACT 
 
This dissertation can be divided in two parts. 
In the first part, my efforts have been focused on the study of the G-
quadruplex structures. 
In chapter one, I describe the unusual arrangement of the DNA to form the 
G-quadruplex structures and their biological role, underlying the reason why 
in the last period a lot of research groups focused their studies on this topic.  
In chapter two, after a brief introduction of the first molecules capable to 
bind the G-quadruplex (Distamicyn A and its derivates), I describe the new 
organic molecule capable to interact with the DNA quadruplex, which I 
have discovered applying some innovative approaches during my PhD. 
In the second part of this thesis I introduce the research conducted in the 
laboratory of Dr. Maria R. Conte at the King’s College of London. In this 
stimulating environment I started studying the structure of the protein LARP4 
and its interaction with a poly (A) RNA using the NMR. 
In the course of my research I have learnt the techniques allowing to do the 
transformation, the expression and the purification of the protein. A summary 
presentation of the techniques I have applied is reported in the second part 
in chapter five. 
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CHAPTER I 
 
G-Quadruplex structures  
 
The double helix structure of duplex DNA is well known. The two antiparallel 
strands are held together by complementary base pairing between adenine 
(A) and thymine (T), and between guanine (G) and cytosine (C), using two 
hydrogen bonds in AT, and three in GC. However, this is not the only base 
pairing arrangement that can occur between bases, and alternative base 
pairing leads to alternative structures, including triple-stranded and four-
stranded structures called G-quadruplex. 
G-quadruplex, as the name suggests, have a core that is made up of 
guanine bases only, with four guanines arranged in a rotationally symmetric 
manner, making hydrogen bonds from N1-O6 and N2-N7 around the edges 
of the resulting square (see figure 1). 
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Figure 1: Four guanines can hydrogen bond in a square arrangement to form a G quartet. 
There are two hydrogen bonds on each side of the square. 
 
These planar structures are called G-quartets, and are stabilized by 
monovalent cations, in particular K+ and to a lesser extent NH4+ and Na+, 
which interact with the alone pairs on the O6 atoms surrounding the central 
core.  
These G-quartets have large π-surfaces, and hence tend to stack on each 
other due to π–π stacking, as well as to enable cations to intercalate 
between the G-quartets. In particular, oligonucleotides with contiguous runs 
of guanine, such as d(TGGGT) can form stacked structures with the G-
quartets linked by the sugar–phosphate backbone. These are called G-
quadruplexes and can form from DNA or RNA strands. They are helical in 
nature due to the constraints of π–π stacking, although for convenience they 
are often depicted without the helicity, as shown in figure 2. 
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Figure 2: G-quartets can stack on top of each other, forming G-quadruplex structures. These 
are held together by π-stacking and the sugar–phosphate backbone. G-quadruplex can 
adopt a range of different stoichiometries and folding patterns. (A) Tetramolecular structure 
with all strands parallel; (B) bimolecular antiparallel structure with adjacent parallel strands; 
(C) unimolecular antiparallel structure with alternating parallel strands; (D) unimolecular 
parallel structure with three double chain reversal loops; (E) unimolecular antiparallel 
structure with adjacent parallel strands and a diagonal loop; (F) unimolecular mixed 
structure with three parallel and one antiparallel strands. All three structures (D), (E) and (F) 
have been observed for the human telomeric repeat. 
 
Since there is a directionality to the strands, customarily described as from the 
5’ end to the 3’ end, there are topological variants possible for these four 
strands. All four strands may be parallel, three parallel and one in the 
opposite direction (antiparallel), or there may be two in one direction and 
two in the other, either with the parallel pairs adjacent to each other or 
opposite each other. A shorthand has arisen which describes all the 
arrangements with at least one antiparallel strand as ‘antiparallel’, although 
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this does not give a full description of the structures. These are depicted in 
figure 2. 
At a molecular level, the different directionality of the strands relates to the 
conformational state of the glycosidic bond between the guanine base and 
the sugar. This may be either syn or anti, as depicted in figure 3. 
O
NN
N
N
NH2
H1'
H8
C2'-endo
d(H1'-H8) = 3.6 Ao
   
O
N
N
N
N
NH2
H1' H8
C2'-endo
d(H1'-H8) = 2.7 Ao
 
Anti       Syn 
 
Figure 3: The bond between the base and sugar can rotate. It has two preferred 
conformations, syn and anti. 
 
When all four strands are parallel, all the bases are in the anti conformation 
and the grooves between the backbones are all of equal size, the system is 
entirely C4 symmetric. When any of the strands are antiparallel, the bases 
must be in the syn form in order for the hydrogen bonds to be formed 
correctly. This then affects the orientation of the backbone relative to the G-
quartets, and hence results in grooves of different sizes. When successive 
guanines (starting with the guanine contributing N1 and N2) are both anti or 
both syn, the groove is medium in size; if the first is anti and the second syn, 
the groove is wider, and if the first is syn and the second anti, then the groove 
is narrower. Thus a G-quadruplex with adjacent parallel strands will be 
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arranged with glycosidic bonds anti–syn–syn–anti, and will have grooves that 
are wide, medium, narrow and medium. In contrast, a structure with 
alternating strands will have glycosidic bonds anti–syn–anti–syn, with grooves 
wide, narrow, wide and narrow. G-quadruplexes may be comprised of four 
separate strands, as in the example above, forming tetramolecular G-
quadruplexes, which are always found in the all antiparallel form. 
Alternatively, they may be formed from two strands, each with two sets of 
contiguous guanines, or just from one strand, folding back on itself to form an 
intramolecular structure. In either of these cases, there will be loops that serve 
to connect the strands of the structure together. Depending on which strands 
are connected, these loops may cross diagonally across the top of the 
structure, joining diagonally opposed antiparallel strands; go across a side, 
linking adjacent antiparallel strands; or may loop around the side of the 
structure linking parallel strands and forming a double-strand reversal loop. 
Some examples of these are shown in figure 2. 
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G-quadruplexes: functions  
 
The important role of these structures in biological systems lies mainly on three 
features: 
• Architecture of telomeres of many organisms 
• G-rich sequences that are present within a wide range of genes 
• Scaffolds of several oligonucleotide aptamers. 
 
Telomeres and telomerase 
 
A fundamental difference in the behavior of normal cells compared to 
tumour cells in culture is that, normal cells divide for a limited number of times 
(exhibit cellular senescence) whereas tumour cells usually have the ability to 
proliferate indefinitely (are immortal). There is substantial experimental 
evidence that cellular aging is dependent on cell division and that the total 
cellular lifespan is measured by the number of cell generations, not by 
chronological time. 
This means there is an intrinsic molecular counting process occurring during 
cell growth that culminates in the cessation of cell division. 
Human telomeres contain long stretches of the repetitive sequence TTAGGG 
which are bound by specific proteins. With each cell division, telomeres 
shorten by 50-200 base pairs, primarily because the lagging strand of DNA 
synthesis is unable to replicate the extreme 3' end of the chromosome, known 
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as the end replication problem (figure 4). 
 
 
Figure 4: A telomere is the region on ends of chromosomes, composed of repeating units of 
6 nucleotides (humans = TTAGGG, repeating 1500 times),without genetic value, capable of 
forming G-quadruplex structures. 
 
When telomeres become sufficiently short, cells enter an irreversible growth 
arrest called cellular senescence. In most instances cells become senescent 
before they can accumulate enough mutations to become cancerous, thus 
the growth arrest induced by short telomeres may be a potent anti-cancer 
mechanism. 
Telomerase, an eukaryotic ribonucleoprotein (RNP) complex, helps to stabilize 
telomere length in human stem cells, reproductive cells and cancer cells by 
adding TTAGGG repeats onto the telomeres using its intrinsic RNA as a 
template for reverse transcription. Telomerase activity has been found in 
almost all human tumours but not in adjacent normal cells. The most 
prominent hypothesis is that maintenance of telomere stability is required for 
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the long-term proliferation of tumours. Thus, escape from cellular senescence 
and becoming immortal by activating telomerase, or an alternative 
mechanism to maintain telomeres, constitutes an additional step in 
oncogenesis that most tumours require for their ongoing proliferation. This 
makes telomerase a target not only for cancer diagnosis but also for the 
development of novel anti-cancer therapeutic agents. One approach to 
telomerase inhibition involves sequestering its substrate, single-stranded 
telomeric DNA, by inducing it to form G-quadruplex structures. There has 
been considerable work on developing G-quadruplex ligands, especially to 
target the human telomeric repeat and hence blocking the action of 
telomerase. 
 
Transcription regulation 
 
Gene transcription is tightly regulated, by a variety of methods. One method 
that is used in some cases is based on the presence of G-quadruplexes 
located in the promoter region of a gene, broadly speaking the kilobase 
upstream of the transcription start site (TSS). This model was originally 
demonstrated by Hurley and co-workers1 for the oncogene c-myc, an 
important transcription factor involved in regulating around 15% of all human 
genes. As a result of this, overexpression of c-myc has been implicated in a 
wide range of cancers including colorectal cancer. Within its promoter there 
is a region, 115–142 base pairs upstream of the TSS, which is highly sensitive to 
 15 
 
nucleases, suggesting that it forms an accessible structure free from histone 
proteins. This region controls the vast majority of the transcription of the gene, 
and studies in vitro of the sequence 
d(GGGGAGGGTGGGGAGGGTGGGGAAGG) show that it is capable of 
forming into a family of polymorphic G-quadruplex, using various 
combinations of the guanine runs underlined. It has further been shown that 
the G-quadruplex ligand TMPyP4 binds to this element leading to down 
regulation of c-myc expression. This clear proof of principle led to the 
proposal that this may be a general mechanism for gene regulation. The 
simplest form of the model (figure 5) suggests that there is an equilibrium 
between two forms of the DNA. On one side the equilibrium is double helix 
DNA, and the transcription occurs as normal; on the other side, one strand is 
separated, and has folded up into a G-quadruplex. This structure then acts as 
a steric block to the transcription. Addition of a G-quadruplex ligand, 
whether a small molecule or a protein, will energetically favour the G-
quadruplex form, and hence move the equilibrium towards that side 
reducing the transcriptional activity. This dynamic equilibrium has been 
experimentally demonstrated. Although this model is presented in terms of 
steric blockage leading to a reduction in transcriptional activity, as was found 
for c-myc, it is also possible that the G-quadruplex form could be an 
activating domain, either because of putative protein recognition of the G-
quadruplex, or because the accessibility of the other strand leads to 
increased transcriptional activity. 
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Figure 5: The formation of a G-quadruplex in a promoter can affect the level and nature of 
transcription from that gene. At the simplest level, it may act as a steric block to the 
transcription machinery. 
 
However, although a wide variety of different genes have now been shown 
to have promoter G-quadruplex, such as VEGF, HIF-1a, Bcl-2, Ret, c-kit and 
KRAS, none have yet had G-quadruplex formation leading to increased 
transcriptional activity. Although in figure 5 the complementary C-rich strand 
is drawn as an unstructured sequence, it is possible that it could form an 
alternative four-stranded structure called an i-motif (figure 6). An i-motif has 
four strands forming a structure somewhat like two interleaved ladders, with 
pairs of strands held together by diagonal CRC+ bonds. These rely on the 
protonation of the N3 of cytosine, which has a pKa of 4.2. As a result, these 
structures are generally only stable under acidic conditions, but the stability 
will clearly be different in the context of chromosomal DNA, especially if a G-
quadruplex structure forms and holds the ends of the i-motif together in the 
correct orientation. 
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Figure 6: A) Two cytosines can pair up, forming three hydrogen bonds, when one of them 
has been protonated. B) Four cytosine containing strands can form an i-motif, with 
interleaved C:C+ bonds. One pair of binding strands is shown in CPK colouring, the other in 
blue/cyan. 
 
Nonetheless, there is still controversy as to the biological relevance of the i-
motif structure. Using the predictive algorithm quadparser, it is possible to 
investigate how many human genes contain G-quadruplex motifs in their 
promoter regions, both to identify novel genes for experimental testing, but 
also to see if there is evidence of over- or under-representation of such 
genes. This analysis has shown that almost half of all genes (43%) contain 
putative G-quadruplex structures in their promoters, which is considerably 
more than would be expected by chance, based on the rest of the genome. 
The enrichment of G-quadruplex motifs occurs increasingly nearer the TSS, 
with the first few hundred bases seeming to be particularly important for G-
quadruplex motifs to be present. Interestingly, genes involved in cancer are 
A B 
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even more likely to have such promoter G-quadruplex, with 67% having such 
sequences. Using the online Gene Ontology database, which describes the 
functions of every human gene, it is possible to see if there is any general bias 
for types of genes that have promoter G-quadruplex. This has revealed that 
genes involved in tightly-regulated processes such as development, 
neurogenesis and cell differentiation are more likely than other classes of 
genes to have promoter G-quadruplex, whereas genes involved in processes 
such as protein biosynthesis, olfaction and immune response are much less 
likely to have promoter G-quadruplex.2 
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Aptamers 
 
Aptamers1 are nucleic acid macromolecules that bind to molecular targets, 
including proteins, with high affinity and specificity. Aptamers have  typically 
from 15 to 40 nucleotides in length and can be composed of DNA and RNA. 
Base composition defines aptamer secondary structure, consisting primarily of 
helical arms and single-stranded loops. Stable tertiary structure, resulting from 
combinations of these secondary structures, allows aptamers to bind to 
targets via van der Waals, hydrogen bonding and electrostatic interaction. 
The conceptual framework and process of aptamer generation emerged 
from pioneering experiments published in the early 90s.2-3 Particularly, Gold et 
al.3 described a process of in vitro aptamer selection, dubbed SELEX 
(Systematic Evolution of Ligand by Exponential enrichment). SELEX is a 
combinatorial chemistry methodology based on oligonucleotide libraries 
which are screened for high affinity binding to a given target. High affinity 
ligands can be isolated from the library using iterative rounds affinity-based 
enrichment, alternating with oligonucleotide amplification. 
The aptamer drug TBA (Thrombin Binding Aptamer), also named ARC183 
(Archemix Corp) is a consensus DNA 15-mer, namely 
5’GGTTGGTGTGGTTGG3’,4,5 discovered with this technique (figure 7).  
 
 21 
 
 
 
Figure 7: Pictorial model of TBA 
 
The three dimensional solution structure of TBA was solved using NMR and X-
ray techniques (figure 8).6,7 TBA is characterized by a chair-like quadruplex 
structure consisting of two G-tetrads connected by two TT loops and a single 
TGT loop. The aptamer is a thrombin inhibitor in development for use as an 
anticoagulant during coronary artery bypass graft procedures. Currently, the 
only approved anticoagulant for coronary artery bypass graft is heparin. TBA 
exhibits a Kd of 2 nM for thrombin, 50 nM for prothrombin, and binding to 
other serum proteins or proteolytic enzymes is essentially undetectable.2 As 
suggested by others,8 TBA binds at the anion exosite I of thrombin in a 
conformation little changed from that of the unbounded species. TBA is a 
strong anticoagulant in vitro, and inhibits thrombin-catalyzed activation of 
fibrinogen, and thrombin induced platelet aggregation. TBA has key 
advantages in that it avoids heparin use and the risk of associated 
thrombocytopenia, is a specific inhibitor with rapid onset, is effective at 
inhibiting clot-bound thrombin, and has a short in vivo half-life of 
approximately 2 min which allows for rapid reversal of its effects and the 
avoidance of dose-adjusting complications of heparin and protamine. 
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Neither significant toxicities nor excessive bleeding intraoperatively has been 
observed. 
 
 
 
Figure 8: Three dimensional solution structure of TBA. 
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CHAPTER II 
Targeting G-quadruplex 
 
Introduction 
 
In the recent years studies on molecules that stabilize the DNA quadruplex 
are becoming increasingly popular, due to the fact that these molecules can 
be used as anticancer agents.  
G-quadruplexes are four-stranded helical DNA or RNA structures, comprising 
stacks of G-tetrads, which are the planar association of four guanines in a 
cyclic Hoogsteen hydrogen-bonding arrangement.1 These structures are 
formed by the folding of one DNA or RNA strand or by the association of two 
or more strands. This results in different combinations of relative strand 
orientations, with consequent formation of grooves of different widths, and a 
number of loop arrangements. From a biological point of view, G-
quadruplexes are widespread in genome and they seem to play a role in a 
number of processes, such as replication, recombination transcription, and 
translation.2 Furthermore, quadruplexes are also found in telomeric DNA.  
Telomers consist of an ensemble of proteins and specialized noncoding DNA 
sequences which protect the ends of the chromosome from damage and 
recombination, and their shortening is implicated in cellular senescence.  
It has been demonstrated that the elongation of telomeric DNA operated by 
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the enzyme telomerase leads cancer cells to an infinite lifetime. Hence, the 
inhibition of telomerase, which is overactive in 85% of tumors, is expected to 
move into the forefront of research for new effective anticancer drugs. 
Since this enzyme requires a single stranded telomeric primer, the formation 
of G-quadruplex complexes by telomeric DNA inhibits the telomerase 
activity. 
In this respect, it has been found that small molecules that stabilize G-
quadruplex structures are effective telomerase inhibitors.3 Quadruplex 
structures offer several recognition sites, most of the interacting molecules 
discovered so far have been found to interact with the wide π-stacking 
surface of the G-tetrads at the 5′ and/or 3′ edges of the quadruplex.4 
The first groove-binder that has been discovered is the Distamicyn A, small 
molecule with antibiotic propriety.5 This molecule is capable to interacts with 
the grooves of the quadruplex [d(TGGGGT)]4 as  antiparallel dimers that bind 
simultaneously two opposite grooves of the quadruplex, adopting a 
particular crescent shape. The complex is also stabilized by four drug/DNA H-
bonds with guanine bases, furthermore there are also strong Coulombic 
interaction between the positively charged amidinium moiety and the 
phosphate groups of the quadruplex. 
Classical intercalation, as observed in the duplex DNA structures, has not 
been demonstrated to date, most probably due to the presence of cations 
like K+ or Na+ in the very center cavity of the quadruplex structures, that 
prevents such a binding mode. Generally, stacking interaction and groove-
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binding modes are characterized by very different specificities. Groove-
binding recognition generally offers a higher extent of selectivity, since it can 
more easily recognize different DNA sequences and, in the case of 
quadruplex structures, can also discriminate among several quadruplex 
topologies, taking advantage of their different groove widths. 
In nature there are a lot of derivatives of Distamicyn A and in this regard 
some molecules have been studied which modify the crescent shape’s 
extensions, changing the number of the pyrrole unitis in the Distamicyn A.6 
These studies demonstrated that the presence of one pyrrole unit more than 
the Distamycyn A, (is the case of compound 1)6 changes both its binding 
mode and its stoichiometry, whilst the addition of two pyrrole units more than 
the Distamicyn A (compound 2)6 causes the minor affinity to the quadruplex 
[d(TGGGGT)]4 (figure 1). 
 
Figure 1: Chemical structures of Distamycin A and its analogues: compound 1 and 
compound 2. 
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Molecules that we can define groove-binders, if compared with intercalate 
agents, have an additional worth: more selectivity and specifity of binding to 
G-quadruplex structures. 
In this chapter I report the work that I have made with my research group 
which has led to the discovery of a new organic molecule capable to 
interact and to stabilize the DNA quadruplex, which probably can become 
an anti-cancer drug because, like other molecules capable to interact and 
stabilize the DNA quadruplex, it could be used as a telomerase inhibitor. 
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Structural and conformational requisites in DNA Quadruplex 
groove binding 
 
Small molecules able to stabilize G-quadruplex have been shown to be 
effective telomerase inhibitors.1,2 These findings have brought a great 
momentum in the study of G-quadruplex binders. So far, most of the reported 
G-quadruplex binding agents bind to DNA by interacting with the wide π-
surface of the G-tetrads at the edges of the quadruplex. Groove-binding 
mode to quadruplex structure was first proposed by Randazzo’s group for the 
Distamycin A,3 and up to now, this is the only molecular entity for which a 
pure groove binding mode has been experimentally proven. The interest in 
the groove binding recognition is mainly fuelled by the chemical and 
conformational differences existing between quadruplex and duplex 
grooves. Unfortunately, the understanding of the chemical, structural, and 
conformational features responsible for G-quadruplex groove binding is still in 
its infancy.  
In this chapter I report a study of a Distamycin A analogue: coumpound 3 
(figure 1), where the major change into the structure is the replacement of 
amidinium group by an uncharged N-methyl amide moiety, to probe the real 
importance of the unique Coulombic interaction in the Distamycin 
A/[d(TGGGGT)]4 complex formation.  
We have used a NMR study to understand the binding mode of the 
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compound, in particular we have performed a NMR titration of compound 3 
with the quadruplex [d(TGGGGT)]4. All the results were confirmed with an 
Isothermal Titration Calorimetric (ITC) study. A molecular and dynamic study 
was developed to have the three-dimensional structure of 3/[d(TGGGGT)]4 
complex.  
 
 
Figure 1: Chemical structure of Coumpound 3 
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Results and discussion 
 
Synthesis of compound 3.  
The novel compound 3 was obtained following the procedure reported in 
the Scheme 1.  
 
Scheme 1: Chemical synthesis of compound 3. 
 
 
Starting from derivative 1, which was prepared following the methodology 
reported in the section Material and method at page 55, we have 
condensed it with 3-amino-N-methylpropanamide hydrochloride4 using an 
excess (2 equiv) of 1-ethyl-3-[3-(dimethylamino) propyl]carbodiimide 
hydrochloride (EDCI) as coupling agent, in DMF and in presence of Hunig’s 
base at room temperature for 18 h. 
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This process has led to the N-methyl carbamoyl derivative 2 in good yield 
after purification by silica gel flashchromatography. The amido modified 
Distamycin A derivative 2 was then transformed in the corresponding 
desformyl compound 3 by treatment of HCl in a mixture of ethanol and 
water. The reason for this last synthetic step was to obtain the hydrochloride 
compound 3, that turned out to be more soluble in pure H2O than derivative 
2 at the concentration used for the preparation of the NMR samples. 
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Nuclear Magnetic Resonance Experiments. 
 
To evaluate the binding properties of compound 3, and to perform a direct 
comparison with the binding behaviour of Distamycin A, [d(TGGGGT)]4 has 
been titrated with 3 at the same experimental conditions (buffer, 
temperature, DNA concentration) used for Distamycin A.3 
As far as Distamycin A is concerned, below 2:1 ligand/quadruplex 
stoichiometry, the addition of Distamycin A to [d(TGGGGT)]4 caused gradual 
changing in chemical shift of the signal of the quadruplex, whereas further 
addition of drug caused the appearance of a new set of proton signals, 
whose intensities rose by increasing the amount of drug with the concomitant 
falling off of the original signals which completely disappeared at a ratio of 
4:1 drug-DNA.  
The NMR titration of compound 3 with the quadruplex is clearly different from 
that observed in the case of Distamycin A (figure 2).  
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Figure 2: NMR titration of [d(TGGGGT)]4 with compound 3 (700 MHz, T = 25 °C). Equivalents 
of the drug are reported on the left of each spectrum. 
 
In fact, the addition of 3 to [d(TGGGGT)]4 caused only gradual changes in 
the chemical shift of DNA proton resonances. 
At ligand/DNA ratio of 4:1, the titration was virtually completed. The four 
strands resulted to be magnetically equivalent throughout the titration, and 
no splitting of resonances was observed at any stage. Moreover, we have 
observed that during the whole NMR titration, a single set of signals was 
present for compound 3 protons, which only grew in intensity and did not 
show any significant change in chemical shift values by increasing ligand 
concentration. These observations suggest that compound 3 binds the 
quadruplex in a fast process on the NMR time scale. 
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To preliminarily evaluate the binding site of compound 3, a comparison of 
resonances of some protons of the uncomplexed DNA and the complexed 
one has been carried out. In particular, I have reported the ∆δ values 
(chemical shifts of the complex minus free DNA) of aromatic, methyl and 
imino protons in figure 3.  
 
Figure 3: Difference in chemical shifts (∆δ) of DNA upon binding of 3 (complex 3:DNA minus 
DNA alone) to [d(TGGGGT)]4. ∆δ values are reported for imino (light gray), aromatic (dark 
gray) and methyl (black) protons. 
 
All the analysed resonances shifted led us to conclude that for the signal of 
the protons of T1 residue there is the least shift, whilst for those of residue T6 
the most. 
In any case, a general shift of the aromatic and imino signals was observed 
also for the G2, G3, G4, and G5; this means that compound 3 is able to 
recognize most of the molecule, even if it recognizes preferentially the 3’ 
edge of the quadruplex. 
An almost complete assignment of the nonexchangeable/exchangeable 
protons of the complex has been accomplished by means of a combination 
of the analysis of 2D NOESY and TOCSY spectra (700 MHz, T = 25°C), in the 
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Tables 1 and 2 we can see the NMR assignment, in figure 4 I have reported 
an expanded region of the NOESY spectrum of the 4:1 3/[d(TGGGGT)]4 
complex. 
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Figure 4: Expanded region of the NOESY (700 MHz, 25°C, mt=100 ms) spectrum of the 4:1 
3/[d(TGGGGT)]4 complex. 
 
Using a 2D TOCSY experiment it was possible to identify, for the DNA, the 1H 
resonances within each deoxyribose; following the analysis of NOEs among 
base protons and H1’, H2’, and H2’’ protons allowed us to assign all base 
protons. The direct comparison of the intensities of the NOESY cross-peaks 
(700 MHz, T = 25°C, mixing time 100 ms) between the H8 proton bases and 
sugar H1’ resonances, and among H8 proton bases and sugar H2’/H2’’ 
resonances, indicates that all Gs residues of the complexed DNA adopt an 
anti glycosidic conformation. Then, all bases have classical H8/H2’-H2’’ 
sequential connectivities to 5’ neighboring, indicating that the four strands 
are involved in the formation of a helical structure. The observation of the 
entire pattern of NOEs has confirmed that the backbone conformation 
resembles closely to conformation of the uncomplexed [d(TGGGGT)]4 
possessing a right-handed B-form helix structure. Each exchangeable proton 
signal was then assigned to the pertinent hydrogen by an in-depth analysis of 
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the NOESY spectra. In particular, the NOE contact between H1 proton of 
DNA at δH 11.34 and the methyl protons at δH 1.34 of the T1 residue led us to 
identify the imino protons belonging to the tetrad that is in proximity of the 5’ 
edge of the quadruplex. Similarly, the identification of the imino protons 
belonging to the tetrad in proximity of the 3’ edge was confirmed by the NOE 
between H1 proton at δH 10.64 and the methyl group at δH 1.66 ppm of the 
thymine T6. The other four H1 resonances of the remaining two central tetrads 
were identified by analysing the NOE connections with the adjacent tetrads. 
The resonances of compound 3 were assigned, first, identifying the 
resonances belonging to the hydrogen on the convex side of the molecule. 
Particularly, the H5 pyrrole protons (δH 6.70, 6.66, and 6.57 ppm for H5-1, H5-2 
and H5-3, respectively) have been assigned taking into account that they 
both exhibit scalar and dipolar coupling with methyls that are linked to the 
same pyrrole ring (δH 3.52, 3.40, and 3.37 ppm for CH3-1, CH3-2, CH3-3, 
respectively). As for the protons on the concave side of compound 3, the H3 
pyrrole protons (δH 6.42, 6.37, and 6.22 for H3-1, H3-2 and H3-3, respectively) 
have been assigned by virtue of very small scalar coupling with H5 protons of 
the same pyrrole ring. Unfortunately, we were not able to assign NH-1, NH-2 
and NH-3 protons due to the presence of ambiguous NOEs with the adjacent 
H3s. The NOESY spectrum of the complex contains a number of 
intermolecular ligand-ligand and ligand-DNA NOEs, in addition to 
intramolecular ones. 
From this careful analysis of NMR spectra we identified ligand-ligand 
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contacts, 12 head to tail NOEs (for each molecule of 3, 24 for each dimer) 
(Table 3), that unambiguously indicates that the ligand molecules bind to the 
quadruplex, two by two, with each term of the dimeric pairs with an 
antiparallel orientation and in close contact to its partner (as observed for the 
binding of Distamicyn A to both duplex and quadruplex DNA).3,5 
 
 
In addition, 14 NOEs were observed between each molecule of compound 3 
and [d(TGGGGT)]4, in particular we found a lot of contact with residues G4, 
G5, and T6 of DNA. Analogously to that observed for Distamycin A, also in this 
case, there are no contacts between compound 3 and the imino protons of 
the quadruplex (since these point inside the quadruplex core) (Table 4). 
 
All this suggests that compound 3 actually does not stack on the edges of the 
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quadruplex, even if it prefers to interact with the 3’ edge of the quadruplex. 
To further confirm that compound 3 is able to bind the grooves of the 
quadruplex, as its analogue Distamicyn A, we have designed and 
synthesized a modified oligonucleotide, namely, d(TGGBrGGT), where dGBr is 
8-bromo-2’-deoxyguanosine, potentially capable to form quadruplex 
structure and possessing a bulky group (bromine) at the very center of the 
grooves. 
We have performed a titration of compound 3 with the modified quadruplex 
d(TGGBrGGT) and then analyzed the titration profile. 
If compound 3 interacts with the portion of the grooves of the quadruplex 
where the bromine is present, this should prevent (or at least should limit) the 
insertion of molecules of compound 3 into the grooves.  
At the first stage of the analysis we have tested the capability of d(TGGBrGGT) 
to form a quadruplex structure, preparing a NMR sample of d(TGGBrGGT) at a 
concentration of 2 mM, in 0.6 mL (H2O/D2O 9:1) buffer solution having 10 mM 
KH2PO4, 70 mM KCl, 0.2 mM EDTA, pH 7.0. The sample was annealed for 5-10 
min at 80°C and slowly cooled down to room temperature, then 1H NMR 
spectra were recorded using DPFGSE pulse sequence for H2O suppression.6,7 
The 1H NMR spectrum (700 MHz, T = 25°C) of d(TGGBrGGT) shows the presence 
of four well-defined singlets in the region 11-12 ppm, attributable to imino 
protons involved in Hoogsteen hydrogen bonds of G-quartets, and the 
presence of five signals (figure 5), belonging to three guanine H8 and two 
thymine H6 protons in the aromatic region.  
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Figure 5: Expanded regions of NMR titration of [d(TGGBrGGT)]4 with compound 3 (700 MHz, 
T=25 °C). Equivalents of the drug are reported on the left. 
 
In figure 5 is clearly indicated that a single well-defined quadruplex species is 
present in solution, consisting of four G-tetrads and possessing a 4-fold 
symmetry with all strands parallel to each other. In a quadruplex like this, 
each Br group of the quadruplex faces right into the grooves, pointing 
outward the quadruplex. 
The quadruplex [d(TGGBrGGT)]4 has been titrated with compound 3 and the 
results are reported in figure 5. The progressive increase of concentration of 
compound 3 up to 4 mol equiv caused only a slight drift of DNA signals and 
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drug resonances to gradually grow in intensity (between 6 and 7 ppm). 
Further additions of drug did not lead to significant changes. As suggested 
also by the ∆δ values of DNA signals (figure 6), the extent of chemical shift 
perturbation is lighter in comparison to the unmodified quadruplex. 
 
Figure 6: Difference in chemical shifts (∆δ) of DNA upon binding of 3 (complex 3:DNA minus 
DNA alone) to [d(TGGBrGGT)]4. ∆δ values are reported for imino (light gray), aromatic (dark 
gray) and methyl (black) protons. No aromatic hydrogens are present for brominated 
residues. 
 
This strongly indicates that, actually, the presence of the bromines at the very 
center of the grooves does affect the recognition process, and that 
compound 3 binds the grooves of [d(TGGGGT)]4. This also suggests that, in 
spite of compound 3 which does not show any NOE contacts with the 5’ 
edge of the groove, it is actually able to span the entire groove. 
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Structure Calculations.  
 
To obtain the three-dimensional structure of the 4:1 complex at atomic level, 
an estimation of proton-proton distances has been retrieved from cross-peak 
intensities in 2D NOESY experiments (700 MHz, T = 25°C). A total of 278 
experimental distance restraints were used for the calculations, and as 
suggested by the presence of eight guanine imino protons in the 1D 1H NMR 
spectrum, 32 supplementary distance restraints (HN1-O6, HN2-N7) for 32 
hydrogen bonds corresponding to the four G-quartets were also 
incorporated during the computations (Table 5).  
 
 
We have collected also restraints for a number of backbone torsion angles; 
the combined analysis of the PE-COSY and zTOCSY experiments revealed 
that all measurable JH1’,H2’ and JH1’,H2’’ ranged from 7 to 9 Hz and from 5 to 6.5 
Hz, respectively, and that a number of cross-peaks for H3′/H4′ correlations 
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were missing. Furthermore, the measurable JH3′, H4′ values were very low. 
This data indicates a predominant S-type nature of sugar ring conformations. 
Therefore, the relative δ angles constraints have been consistently 
constrained into the range 95°/175°.8 Very interesting information could be 
also retrieved from the analysis of the sum of H4′ couplings constant (ΣJH4′ = 
JH4′,H3′ + JH4′,H5′ + JH4′,H5′′). All measured ΣJH4′ turned out to be <10 Hz. This, along 
with the lack of intense NOEs between H8 and any H5′/H5′′ protons, 
suggested that γ angles could be constrained in the range 20°/100°.8 As far 
as β and ε angles are concerned, their estimation have been performed 
measuring the scalar coupling in the 2D proton-detected heteronuclear 1H-
31P COSY and by using the semiempirical Karplus equation.8 Thus, since for all 
JP,H5′ and JP,H5” were <8 Hz, β backbone torsion angles were restricted to -230°/ 
-110°.8 On the contrary, JP,H3′ for residues 2, 3, 4, and 5 were larger than 8 Hz, 
and the corresponding ε angles were restricted to -230°/-110°.8 Furthermore, 
since α (O3′-P-O5′-C5′) and ζ (C3′-O3′-P-O5′) dihedral angles do not involve 
any protons, it has been impossible to directly retrieve structural information 
for these angles. Nevertheless, since in a structured DNA α and ζ angles 
cannot be considered independent from β, γ, δ and ε, we thought 
opportune to restraint at least one of these angles; thus, α angles have been 
constrained in the wide range -150°/-30°. Finally, due to the presence of very 
weak NOEs between H8 and H1′ hydrogens, glycosidic torsion angles χ were 
fixed in the anti-domain (-155°/-75°). Therefore, 3D structures which satisfy 
NOEs and dihedral angles were constructed by simulated annealing (SA) 
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calculations. A total of 100 structures were generated, and among them, the 
10 best models were selected based on the value of the overall potential 
energy and NMR restraint violations for further simulations. In figure 7 is shown 
the representative ligand/DNA conformations (it is the ones with the lowest 
rmsd value with respect to the average structure calculated over the whole 
production run). 
 
Figure 7: A) Side view and B) bottom view of the superimposition of the 10 best structures of 
the 4:1 3/[d(TGGGGT)]4 complex. compound 3 is reported in green; DNA is colored in yellow. 
 
As expected, differently from what demonstrated for Distamycin A, 
compound 3 dimers are shifted toward the 3′ end of the quadruplex. The two 
staggered antiparallel 3 molecules overlap for their total length with each N-
methylpyrrole ring of one molecule contacting the terminal amide bond of 
the other, thus, making synchronized twisting to easily fit the curvature of the 
DNA quadruplex grooves. Moreover, one molecule of the dimer of 
compound 3 is more solvent exposed, while the other is sandwiched 
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between the first one and the quadruplex structure (herein referred as 3ex 
and 3in, respectively). The preference for such an orientation with respect to 
the G-quadruplex could be ascribable to the absence of a positively 
charged anchoring point that in Distamycin A stabilizes each monomer so as 
to project the methyl groups toward the solvent and the opposite amide 
protons toward the crevice of the groove. 
Compound 3 interact with the quadruplex in an antiparallel fashion, as its 
analogue Distamycin A, this is a very interesting result because, in theory, two 
possible orientations could be predicted for a dimer of 3: parallel and 
antiparallel. This behavior could be imputed to the charge-transfer π-π 
interactions and to the energetically favorable dipole-dipole interactions 
established between the monomers as demonstrated by the dipole moments 
of the two staggered structures which are pointing in opposite directions 
(figure 8). 
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Figure 8: NMR structure of the compound 3 dimer. Dipole moments are displayed as arrows. 
 
The crescent shape of the ligand allows the formation of favorable 
interactions with the quadruplex by following the curvature of the grooves in 
the G4-G5 region and taking contact with T6 at the 3′ end. 
Comparing our structural results with the dates of the Distamycin A, is clear 
that in both compounds a crescent shape is adopted, but the conformation 
of compound 3 alone does not guarantee a pure groove binding mode in 
the [d(TGGGGT)]4; this is an important difference with the Distamycin A 
because in the Distamycin A the crucial anchoring positively charged point 
(amidinium group) and the crescent shape conformation are both 
responsible for a pure groove binding mode. 
Calculation of the Delphi electrostatic potential surface reveals that the 
terminal methylcarboxamide groups of the compound 3 dimer are hosted in 
rather polar regions of the quadruplex while the terminal pyrrole ring is 
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exposed to the solvent in the G4 region in 3ex or embedded in a less 
hydrophilic environment in the T6 region in 3in (figure 9).  
 
Figure 9: Electrostatic potential surface of the representative structure. The surface of the 
quadruplex is colored according to electrostatic potential, more positive potentials are 
colored in blue and more negative potentials are colored in red. 3in and 3ex are 
represented as magenta and green sticks, respectively. 
 
A close-up view of the best binding pose resulting from NMR constrained SA 
experiments reveals that the aforementioned terminal groups of 3 are 
involved in a network of H-bonds with the quadruplex (figure 10).  
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Figure 10: Side view representation of the 4:1 complex 3/[d(TGGGGT)]4. 3in, 3ex, and 
[d(TGGGGT)]4 are depicted in magenta, green, and yellow sticks, respectively. 
 
Most precisely, the flexible carboxamide terminal group of the 3in molecule is 
kept in place by an intramolecular H-bond between its NH-4 proton and the 
carbonyl oxygen attached to the third pyrrole ring and by an intermolecular 
one established between the terminal carbonyl oxygen of 3in and the 
terminal NH2 group of 3ex. Moreover, the G5 base is contacted by the dimer 
through two H-bonds between its O4′ and its N3 atoms with the 3ex NH2 and 
3in NH-4 groups, respectively. While polar contacts mainly govern the 
recognition between the compound 3 dimer and the center of the 
quadruplex groove, rather hydrophobic interactions are established with the 
3′ end of the [d(TGGGGT)]4 structure. Notably, the terminal pyrrole ring of the 
3in molecule is embedded in a sort of aromatic cage formed by the two T6 
bases of the groove and the third pyrrole of the 3ex molecule. 
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Isothermal Titration Calorimetry Measurements.  
 
Thanks to the great advances in the sensitivity and reliability of the 
calorimeter, ITC has become an important tool for the direct measurement of 
thermodynamic parameters in several biological interactions. Moreover, it 
has been proven to be useful to study the energetic aspects of interactions 
between G-quadruplexes and other molecules, including small ligands.9 
Therefore, we have utilized ITC to characterize the thermodynamics of 
binding of compound 3 to [d(TGGGGT)]4 quadruplex. 
Figure 12 shows the binding isotherm resulting from the integration of raw 
data after correction for the heat of ligand dilution. The calorimetric data 
indicates an endothermic interaction. 
 
Figure 12: Normalized heat of interaction between compound 3 and [d(TGGGGT)]4. The 
squares represent the experimental data obtained by integrating the raw data and 
subtracting the heat of ligand dilution into the buffer. The line represent the best fit obtained 
by a nonlinear least-squares procedure based on a single set of identical sites model. 
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After a number of injections of ligand, increasingly less heat uptake was 
observed until constant values were obtained (corresponding to the heat of 
dilution), reflecting a saturable process. The values of Kb and ∆H° derived by 
ITC enable us to complete the thermodynamic binding profiles by calculating 
corresponding values of T∆S° and ∆G°. The resulting thermodynamic 
parameters are showed in Table 6.  
 
The binding affinity measured from ITC is 9 x 105 M-1 at 25°C. The binding 
enthalpy was found to be positive (∆H°= 6 kJ mol-1) and the stoichiometry of 
interaction was found to be 4:1 ligand-quadruplex. 
Inspection of the data reveals that the entropic contribution (T∆S° = 40 kJ 
mol-1) to the binding of compound 3 to the quadruplex provides the driving 
force for the ligand-quadruplex binding reaction, while the positive heat of 
formation of the complex indicates that this interaction is an enthalpically 
unfavorable process. The results from the calorimetric titration data alone do 
not allow us to demonstrate with certainty the binding mode of this ligand. 
Usually, small molecules bind to duplex DNA by two predominant binding 
modes, intercalation and groove binding. Calorimetric studies have 
determined the enthalpic and entropic contributions to the DNA binding of 
representative DNA binding compounds. Generally, the binding of an 
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intercalator to DNA is driven by a large favorable enthalpy change and by 
an unfavorable entropy decrease, while the binding of a groove binder to 
DNA is characterized by a large favorable increase of entropy and a small 
favorable or unfavorable enthalpy change.10 
In the case of the binding of compound 3 to [d(TGGGGT)]4, the 
thermodynamic data determined by ITC are in agreement with the groove 
binding profile and are confirmed by the structure of the complex. The 
thermodynamic parameters for the interaction of compound 3 are slightly 
different from the ones determined by ITC for the binding of Distamycin A to 
the same quadruplex molecule. In both cases, the driving force for the 
binding reaction is the entropy change. However, the binding of compound 
3 shows a small unfavorable enthalpy change, while in the case of 
Distamycin A, a small favorable enthalpy change was observed. This 
interesting difference is probably due to structural features of the two ligands, 
probably the positively charged amidinium moiety of Distamycin A interacts 
with the phosphate groups of the quadruplex, providing a favourable 
(although small) enthalpy contribution, while in the compound 3, the 
amidinium group is replaced by the uncharged N-methyl amide moiety that 
cannot give this contribution. 
In summary, the structural data herein reported unveil the role of the 
Coulombic interaction engaged by Distamicyn A and the quadruplex. Such 
an interaction not only influences the strength of ligand/quadruplex 
formation, but surprisingly governs the orientation of the ligand with respect 
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to the DNA. In fact, the removal of the positively charged terminal group 
results in an unprecedented ligand binding position in which both the groove 
and the 3’ end of the DNA are occupied. Furthermore, the lack of charge in 
the ligand does not affect the relative orientation of two molecules of 
compound 3 forming a dimer. All this opens up the tempting opportunity for a 
fine-tuning of the drug-quadruplex interaction mode. Moreover, with this 
further contribution, we provided the scientific community with an enhanced 
knowledge of the structural and conformational demands of the quadruplex 
groove that will serve as a platform for a rational design of novel groove 
binding agents. 
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Material and method  
 
Oligonucleotide synthesis 
 
The oligonucleotide d(TGGGGT) was synthesized on a Millipore Cyclone Plus 
DNA synthesizer using solid phase β-cyanoethyl phosphoramidite chemistry at 
15 µmol scale. Commercially available 5’-DMT-aminoprotected-8-
bromodeoxyguanosine- 3’-phosphoramidite was used for the preparation of 
the modified oligonucleotide d(TGGBrGGT). The latter was assembled using 
the standard solid phase β-cyanoethylphosphoramidite chemistry. The 
oligomers were detached from the support and deprotected by treatment 
with concentrated aqueous ammonia at 55 °C for 12 h. The combined 
filtrates and washings were concentrated under reduced pressure, 
redissolved in H2O, analyzed, and purified by high-performance liquid 
chromatography (HPLC) on a Nucleogel SAX column (Macherey-Nagel, 
1000-8/46), using buffer A, 20 mM KH2PO4/K2HPO4 aqueous solution (pH 7.0), 
containing 20% (v/v) CH3CN; buffer B, 1 M KCl, 20 mM KH2PO4/K2HPO4 
aqueous solution (pH 7.0), containing 20% (v/v) CH3CN; a linear gradient from 
0 to 100% B for 30 min and flow rate 1 mL/min were used. The fractions of the 
oligomer were collected and successively desalted by Sep-pak cartridges 
(C-18). The isolated oligomers proved to be >98% pure NMR. 
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Synthesis of N-[5-({[5-({[3-Amino-3-(N-methylcarbamoyl)-
ethyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-
1-methyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H pyrrole-2-
carboxamide (2).  
 
A solution of 3-amino-N-methylpropanamide hydrochloride (123 mg, 1.2 
mmol) in dry DMF (8 mL) was cooled to 5 °C and N, N’-diisopropylethylamine 
(206 mL, 1.2 mmol) was added. After 10 min, the acid 1 (412 mg, 1 mmol.) 
and then EDCI (384 mg, 2 mmol) were added. The reaction mixture was 
stirred at room temperature for 18 h, the solvent evaporated in Vacuo, and 
the crude residue purified by flash chromatography. The crude product 
purified by chromatography on a silica gel column, using DCM/MeOH (8:2) 
as eluent, furnished the compound 2 as a white solid (367 mg, 74% yield). Mp 
= 156-158 °C; IR (KBr): 3420, 3310, 1665, 1554, 1312, and 1212 cm-1; 1H NMR 
(DMSO-d6) δ: 2.42 (m, 2H), 2.77 (m, 3H), 3.34 (m, 2H), 3.78 (s, 3H), 3.82 (s, 3H), 
3.83 (s, 3H), 6.65 (d, J ) 1.6 Hz, 1H), 6.83 (d, J ) 1.6 Hz, 1H), 6.82 (d, J ) 1.6 Hz, 1H), 
7.01 (d, J ) 1.6 Hz, 1H), 7.17 (d, J ) 1.6 Hz, 1H), 7.22 (d, J ) 1.6 Hz, 1H), 7.89 (bs, 
1H), 8.08 (s, 1H), 8.13 (s, 1H), 8.18 (s, 1H); 9.91 (s, 1H), 9.94 (s, 1H). FABMS 
(MALDI-TOF): 497.8 [M + 1]+. 
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Synthesis of 4-Amino-N-[5-({[5-({[3-amino-3-(N-
methylcarbamoyl)ethyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-
yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-
2-carboxamide (3). 
 
To 5 mL of a solution obtained by the addition of 24 mL of ethanol (95%) to 1 
mL of 36% HCl in water was added compound 2 (248 mg, 0.5 mmol), and the 
mixture stirred at room temperature for 24 h. After this time, the reaction was 
filtered, the residue washed with dry ethyl ether (5 mL), and then dried on 
P2O5, to furnish compound 3 as brown solid. Mp = 262-264 °C; 1H NMR (DMSO-
d6) δ: 2.41 (m, 2H), 2.56 (m, 3H), 3.24 (m, 2H), 3.78 (s, 3H), 3.80 (s, 3H), 3.81 (s, 
3H), 6.75 (d, J) 1.6 Hz, 1H), 6.82 (d, J ) 1.6 Hz, 1H), 6.84 (d, J ) 1.6 Hz, 1H), 6.96 (d, 
J ) 1.6 Hz, 1H), 7.04 (d, J ) 1.6 Hz, 1H), 7.20 (d, J ) 1.6 Hz, 1H), 7.88 (bs, 1H), 8.12 
(s, 1H), 9.92 (s, 1H), 9.96 (s, 1H), 10.20 (bs, 3H). FAB-MS (MALDI-TOF): 469.4 [M + 
1]+. 
 
Nuclear Magnetic Resonance Experiments.  
 
The quadruplex NMR sample was prepared at a concentration of 2 mM (8 
mM single strand concentration), in 0.6 mL (H2O/D2O 9:1) buffer solution 
having 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA, pH 7.0. For D2O experiments, 
the H2O was replaced with D2O by drying down the sample, followed by 
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lyophilisation and redissolution in D2O alone. NMR spectra were recorded with 
Varian UnityINOVA 700 MHz spectrometer. 1H chemical shifts were referenced 
relative to external sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS). 1D 
proton spectra of the sample in H2O were recorded using pulsed-field 
gradient DPFGSE6,7 for H2O suppression. Phase-sensitive NOESY spectra11 were 
recorded with mixing times of 100 and 200 ms (T = 25 °C). Pulsed-field 
gradient DPFGSE6,7 sequence was used for NOESY experiments in H2O. 
TOCSY12 and zTOCSY13 spectra with mixing times of 100 ms were recorded 
with D2O solution. All experiments were recorded using STATES-TPPI14 
procedure for quadrature detection. In all 2D experiments, the time domain 
data consisted of 2048 complex points in t2 (16K in the zTOCSY) and 400-512 
fids in t1 dimension. The relaxation delay was kept at 3s for NOESY 
experiments used in the structure determination. A relaxation delay of 1.2 s 
was used for all other experiments. The NMR data were processed on a SGI 
Octane workstation using FELIX 98 software (Accelrys, San Diego, CA) and on 
iMAC running iNMR software (www.inmr.net). 
 
Isothermal Titration Calorimetry.  
 
ITC measurements were conducted at 25 °C on a CSC 4200 Calorimeter from 
Calorimetry Science Corporation (Lindon, UT). In these experiments, 10 µL 
aliquots of a 1250 µM ligand solution were injected into a sample cell 
containing 1300 mL of 40 µM quadruplex solution, with stirring at 297 rpm, for 
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a total of 25 injections. The delay between injections was 400 s. Each ligand 
injection produced a heat burst curve. The areas under these heat burst 
curves were determined by integration to yield the associated injection 
heats. The heats of dilution were determined in parallel experiments by 
injecting a ligand solution of the same concentration in the same buffer. The 
heat of dilution was subtracted from the interaction heats prior to curve 
fitting. The corrected heat values are plotted as a function of the molar ratio, 
to give the corresponding binding isotherms. The resulting isotherms were 
then fitted to a single set of identical sites model using the Bindwork program 
supplied with the instrument, to give the binding enthalpy (∆H°), equilibrium 
binding constant (Kb), and stoichiometry (n). The remaining thermodynamic 
parameters, ∆G° and T∆S°, were derived using the standard relationships ∆G° 
= -RT ln Kb and T∆S° = ∆H° - ∆G°. The buffer conditions used for ITC 
measurements were the same of NMR experiments. 
 
Structure Calculations  
 
Restrained Simulated Annealing (SA) calculations were performed using the 
AMBER 10.0 package,15 with DNA described by the latest AMBER force field 
for nucleic acids (ff99bsc0),16,17 while compound 3 was parameterized using 
the General AMBER Force Field.18 The Jaguar software package 
(Schrodinger) was used to calculate atomic charges using DFT with an HF/6-
31G** basis set at the B3LYP level. For the initial AMBER model, compound 3 
 59 
 
was manually docked into two opposite grooves of the [d(TGGGGT)]4 using 
as a reference structure the Distamycin A/[d(TGGGGT)]4 solution structure 
(PDB code 2JT7).12 In fact, given the presence of many head to tail ligand-
ligand NOEs, as happened for Distamycin A, also compound 3 is expected to 
bind the quadruplex structure in a dimeric antiparallel form. Each 3 dimer was 
then placed into the quadruplex groove consistently with what recorded in 
NMR experiments. For annealing simulations, the General Born solvation (igb = 
2) with monovalent salt concentration corresponding to 0.1 M was used. The 
complex was heated to 900 K in the first 5 ps, cooled to 100 K for the next 13 
ps, and then cooled to 0 K for the last 2 ps. The temperature of the system 
was maintained with a varying time constant: 0.4 ps during heating, 4 ps 
during cooling to 100 K, 1 ps for the final cooling stage, and then reduced 
from 0.1-0.05 for the last picosecond. The force constants for NOE constraints 
were increased from 3 to 30 kcal mol-1 Å-2 during the first 5 ps and then 
maintained constant for the rest of the simulation. These force constants were 
applied in the form of a parabolic, flat-well energy term where r is the model 
distance or torsion angle and k is the respective force constant. 
 
             Econstraint = k(r2 - r)2  r1 ≤ r ≤ r2 
                Econstraint = 0  r2 ≤ r ≤ r3 
                        Econstraint = k(r3 - r)2  r3 ≤ r ≤ r4 
 
The values for r1 and r4 represent upper and lower distance bounds, defining 
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the linear energetic penalty before and after the flat-well energy term. The 
applied distance NOE constraints were retrieved by cross-peak volume 
integrations performed with the program FELIX 98 (Accelrys, San Diego, CA), 
using the NOESY experiment collected at mixing time of 100 ms. The NOE 
volumes were then converted to distance restraints after they were 
calibrated using known fixed distances. The NOE restraints were generated 
with three distance classifications as follows: strong NOEs (r2 = 1.0 Å; r3 = 3.5 
Å), medium NOEs (r2 = 3.0 Å; r3 = 4.5 Å), and weak NOEs (r2 = 4.0 Å; r3 = 6.0 
Å). Distance constraints between base pairs, set at half the NOE distance 
constraint strength, were applied to maintain hydrogen bonding (as 
indicated by the observation of imino proton resonances). Hydrogen bonds 
constraints were used in the range of 1.7 Å (r2)/2.3 Å (r3). Planarity force 
constraints of 200 kcal mol-1 rad-2 were applied to G bases throughout the 
simulations. In agreement with NMR data, the backbone torsion angles α, β, 
γ, δ and ε were restrained in the range -150°/-30°, -230°/-110°, 20°/100°, 95°/ 
175°, and -230°/-110°, respectively.8 Further, glycosidic torsion angles χ were 
fixed in the anti domain (-155°/-75°). Interactions within the system were 
calculated. An unrestrained energy minimization step completed the 
simulated annealing run. This simulated annealing/energy minimization 
procedure was repeated 100 times. Ten best models were selected based on 
the value of the overall potential energy and NMR restraint violations for 
further analysis. After charge neutralization by the addition of 20 K+ ions, the 
complexes were solvated with 16758 water molecules in a TIP3P pre-
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equilibrated box.19 Several equilibration steps were performed comprising 
minimization of the solvent molecules with the DNA and ligand fixed, 
minimization of the whole system, and slow heating to 300 K with weak 
positional restraints on DNA and drug atoms under constant-volume 
conditions. The following 5 ns production runs were applied in the NPT 
ensemble. The particle mesh Ewald method20 was used to evaluate the 
electrostatic interactions with a direct space sum cut off of 10 Å. With the 
bond lengths involving hydrogen atoms kept fixed with the SHAKE algorithm, 
a time step of 2 fs was employed.21 Related conformational substates 
populated during the molecular dynamics simulation were analyzed with the 
AMBERS’s PTRAJ module.22 For the 10 trajectories, the average configuration 
was taken as a reference for subsequent mass-weighted rmsd calculations 
considering all atoms excluding terminal T bases. The single snapshot of each 
trajectory with the lowest rmsd was taken as the representative dynamic 
structure of that simulation. 
The final set of coordinates has been deposited in the Protein Data Bank 
(accession code: 2KVY). 
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Tandem application of Virtual Screening and NMR experiments in 
the discovery of brand new DNA Quadruplex groove binders. 
 
To find new quadruplex groove binding agents, the chemical nature of the 
quadruplex grooves must be considered. Interestingly, all known quadruplex 
structures are characterized by grooves that are chemically and 
conformationally very different from the minor groove of the duplex DNA. This 
means that searching for new quadruplex groove binding agents among 
duplex minor groove binders may not be the most successful strategy. For this 
reason, a number of research groups have recently focused their attention 
on finding alternative molecular scaffolds able to recognize the groove of 
the quadruplex.1,2 In this work, I attempted to search for brand new 
molecular scaffolds able to interact with the groove of quadruplex structures 
by means of a structure-based virtual screening (VS) approach.3  
Actually, whereas there are numerous studies using these screening methods 
for targeting proteins, only few VS campaigns have been undertaken 
targeting nucleic acids, and, to the best of our knowledge, none targeting 
the groove of the quadruplex. In a recent review, Trent and co-workers4 have 
outlined that the software Autodock optimally balances docking accuracy 
and ranking. Thus, as a starting point, this program was used in VS 
experiments aimed at targeting a very simple quadruplex, namely 
[d(TGGGGT)]4 (PDB code 1S45).5 This quadruplex possesses a 4-fold symmetry 
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with all strands parallel to each other, which afford four grooves of identical 
medium width, and all nucleosides in an anti glycosidic conformation. Thus, 
the docking software Autodock4 (AD4) was used to dock a diversity set from 
the commercially available Life Chemicals database (6000 compounds). To 
avoid finding redundant information, a search area large enough to enclose 
only one of the four identical grooves was used (figure 1).  
 
Figure 1: Surface representation of the quadruplex structure. Orange, white and cyan areas 
represent negatively, neutrally and positively charged regions, respectively. The grey box 
represents the searched area in VS calculations. The cyan transparent arrow outlines the 
groove area taken into consideration. 
 
The VS results were sorted on the basis of their predicted binding free 
energies (∆GAD4) which ranged from -0.95 to -9.55 kcal/mol. Solutions with a 
predicted binding free energy greater than -6.0 kcal/mol and a cluster size 
lower than 10 out of 100 individuals were discarded. Based on these criteria 
only 137 individuals were retained for further consideration. The binding poses 
calculated for these compounds were then visually inspected to discard all 
the individuals which were not predicted to establish tight interactions with 
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the groove of the quadruplex structure. More precisely, compounds that 
were not able to form H-bonds with any of the guanine bases and/or to 
establish an electrostatic interaction with the backbone phosphate groups 
were not considered. After this final step, 30 compounds (figure 2) 
corresponding to 0.5% of the original Life Chemicals database were selected 
and purchased for further analysis.  
 
 
Figure 2: 30 compounds selected.  
 
The experimental test of the top computational “hits” for binding has been 
performed by NMR, which has the significant advantages of being able to 
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detect weak binders and readily identify the ligand binding sites, 
consequently verifying the binding specificity.6 Thus, we prepared 30 identical 
DNA samples containing 6.8 mM of d(TGGGGT) in 0.2 mL (H2O/D2O 9:1) of 
buffer solution having 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA, at pH 7.0.  
The first problem that we encountered in testing the selected compounds 
was the solubility (most of them were not soluble in water). Nevertheless, all 
samples turned out to be soluble in DMSO. 
So far each titration of a new compound with a quadruplex structure was 
done in water; we had to understand if the quadruplex [d(TGGGGT)]4 
maintain the same features in DMSO, for this reason we have tested the 
stability of the quadruplex [d(TGGGGT)]4 in buffers containing different 
percentages of DMSO. The quadruplex turned out to be perfectly structured 
even in buffer solutions containing 30% of DMSO. 
After this results, we dissolved each equivalent of the selected compounds in 
5 µL of DMSO, in such a way to gain an overall percentage of DMSO at the 
end of the titration not higher than 15%. The NMR titrations (700 MHz, T = 25°C) 
were carried out monitoring resonance chemical shift changes of DNA, 
which were used to estimate whether a given compound is able to interact 
with the quadruplex and to determine the binding site. In line with the 
expected results of a VS campaign, a number of false positives were found 
(figure 3):  
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• 9 molecules did not significantly interact with the quadruplex 
• 6 molecules caused a shift of the signal of Ts (T1 and T6) 
• 9 molecules caused a shift of the resonances belonging to external 
bases (T1 and G2, T6 and G5), most probably due to an end-stacking 
interaction 
• 6 molecules were found to cause an appreciable shift, among the 
others, of the G3 and G4 resonances signals, thus suggesting, as 
expected, a groove binding interaction.  
 
Molecules which did not interact with the quadruplex 
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Molecules interacting with Ts 
 
Molecules interacting as end-stackers 
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Molecules interacting as groove-binders 
 
 
 
 
 
 
 
Figure 3: Structures of the newly identified groove binders. I have divided the 30 compounds 
selected by Virtual Screening in the several groups: Molecules not interacting with the 
quadruplex; Molecules only interacting with the Ts; Molecules interacting as end-stakers.; 
Molecules interacting as groove binders.  
The Life Chemicals codes have been reported only for the six groove binders, numbered 
from 1 to 6. 
 
More in details, compounds 1-5, belonging to the group of molecules 
interacting as groove binders, provided NMR titration profiles very similar to 
each other, causing mainly drifting of the signals of G3, G4, G5, and T6, and 
so indicating that the recognition process involves mostly the 3′ side of the 
grooves (figure 4).  
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Figure 4: NMR titration profiles of compounds 1-6. We can see the compounds 1-5 causing 
mainly drifting of the signals of G3, G4, G5, and T6, the recognition process involves mostly 
the 3′ side of the grooves. The compound 6 causes a major change of the resonances of the 
quadruplex, suggesting a higher affinity. On the top of each NMR titration profile I have 
reported the 1D 1H-NMR spectrum of the compound alone in DMSO-d6 and on the bottom I 
have reported the NMR titration of [d(TGGGGT)]4 with the compound. 
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On the other hand, the compound 6 seems to entirely span the grooves, 
perturbing more uniformly all the residues of the quadruplex, in addition it 
causes a major change of the resonances of the quadruplex, suggesting a 
higher affinity. 
This is a very interesting result, since it is surprisingly consistent with the mode of 
binding calculated by the VS (figure 5).  
 
Figure 5: Binding poses calculated by AD4 for compounds 1-6 in the considered quadruplex 
structure. DNA is represented as spheres with the 5’ at the top and the 3’ at the bottom. 
Orange, white and cyan spheres represent negatively, neutrally and positively charged 
regions, respectively. Ligands are depicted as white sticks. 
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Interestingly, while compounds 1-4 and 6 are positively charged as most of 
the already known groove binders, compound 5 does not possess any 
charge, so that the binding might be more driven by the presence of a 
number of H-bond acceptor heteroatoms. The titration of all 6 molecules 
turned out to be virtually completed at 4 equiv. 
In order to confirm the results obtained with the new approach of Virtual 
Screening and to find new molecular scaffolds able to interact with the 
groove of the DNA quadruplex [d(TGGGGT)]4, we decided to make a novel 
NMR titration experiments where we used a modified quadruplexes, namely 
[d(TGGBrGGT)]4 and [d(TGGGGBrT)]4. The novel NMR spectroscopy 
experiments combined with molecular modelling studies, allows for a more 
detailed pictures of the interaction between each binder and the 
quadruplex DNA, also an Isothermal Titration Calorimetry (ITC) measurements 
was used to confirm the results  
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Results and discussion 
 
NMR and molecular modelling studies 
 
Using NMR, six molecules (1-6, figure 3) were found to be potential groove 
binders: they cause an appreciable shift, amongst others, of the signals of G3, 
G4, G5 and T6 of the parallel quadruplex [d(TGGGGT)]4, indicating that the 
recognition process involves mostly the 3’ side of the grooves, a result also 
confirmed  by the virtual screening calculations.7 
In order to get further insights into the binding mode of compounds 1-6, we 
have acquired a number of NOESY experiments of the complexes of the six 
compounds with the quadruplex [d(TGGGGT)]4. Unfortunately, as no 
diagnostic NOE cross-peak could be retrieved for any complex, none of the 
three-dimensional structures at atomic level could be determined.  
Thus, we decided to get a more detailed picture of the interactions from the 
NMR titration of modified quadruplexes and from molecular docking 
calculations. As a result, we designed and synthesised modified 
oligonucleotides, namely d(TGGBrGGT), d(TGGGBrGT) and d(TGGGGBrT), 
where dGBr is 8-bromo-2’-deoxyguanosine, potentially capable of forming 
quadruplex structures and possessing a bulky group (bromine) at different 
positions of the grooves (G3, G4 and G5), as this portion of the DNA should be 
involved in 1-6 recognition.8 
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All the new six scaffolds individuated were titrated with the modified 
quadruplexes . An analysis of the NMR titration’s results profile was then 
carried out. 
The rationale behind these experiments relies on the assumption that if these 
compounds interacted with the quadruplex groove region, the presence of 
the bromine group should have prevented (or at least limited) the 
ligand/DNA interactions. 
Prior to these experiments, we tested the capability of d(TGGBrGGT), 
d(TGGGBrGT) and d(TGGGGBrT), to form a quadruplex structure.9 
Their NMR samples were prepared at a concentration of 2 mM, in 0.6 ml 
(H2O/D2O 9:1) buffer solution having 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA, 
pH 7.0. These samples were then annealed for 5-10 min at 80 °C and slowly 
cooled down at room temperature, then 1H NMR spectra were recorded by 
using DPFGSE pulse sequence for H2O suppression.10,11 The 1H NMR spectra 
(700 MHz, T = 25 °C) of d(TGGBrGGT) and d(TGGGGBrT) show the presence of 
four well defined singlets in the region 11-12 ppm, ascribable to imino protons 
involved in Hoogsteen hydrogen bonds of G-quartets, as well as the 
presence of five signals belonging to three guanine H8 and to two thymine 
H6 protons in the aromatic region. This indicates that a single well defined 
quadruplex species is present in solution for both molecules, consisting of four 
G-tetrads and possessing a four fold symmetry with all strands parallel to each 
other. On the other hand, the 1D 1H NMR spectrum of d(TGGGBrGT) shows the 
presence of a great number of signals in the regions of imino and aromatic 
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protons, suggesting that d(TGGGBrGT) is affected by structural heterogeneity, 
thus preventing its use in our experiments. Hence, only the quadruplexes 
[d(TGGBrGGT)]4 and [d(TGGGGBrT)]4 were titrated with compounds 1-6 and 
the titrations monitored by NMR. 
A comparison of resonances of protons of the uncomplexed quadruplex and 
the complexed one has been performed, in particular we have studied the 
∆δ values (chemical shifts of the complex minus free DNA) of aromatic, 
methyl and imino protons. 
As far as compound 1 is concerned, the titration with unmodified quadruplex 
[d(TGGGGT)]4 led to a general shift of the monitored signals (white bars in 
figure 6).  
 
Figure 6: ∆δ values of aromatic (H6/H8), methyl (Me) and imino protons (NH) for 
[d(TGGGGT)]4 (white bars), [d(TGGBrGGT)]4 (light-grey bars) and [d(TGGGGBrT)]4 (dark-grey 
bars). Asterisks indicate a severe line broadening of the monitored signals. Arrows indicate 
the lack of bars due to the presence of bromine atoms. 
 
On the other hand, the titration of [d(TGGBrGGT)]4 causes a slight shift (light-
grey bars in figure 6) of the residues at the 3’ edge of the quadruplex, namely 
G5-H8, T6-H6/Me, and only of T1-H6/Me at 5’ edge, whilst no appreciable shift 
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can be measured for the other signals. This means that the bromine atom at 
the very centre of the groove did affect the binding of compound 1, and 
that it can be confidently considered a groove binder. Furthermore, the 
titration of [d(TGGGGBrT)]4 led to a severe line broadening of all signals, 
making impossible to retrieve any information from the spectra. This NMR 
phenomenon can be interpreted assuming that the ligand is changing its 
binding pose on the NMR time scale. 
It is noteworthy that compounds 1-6 have been discovered from the virtual 
screening approach and in that study Autodock4 program was used with a 
search area large enough to enclose only one of the four identical grooves 
to avoid redundant information.8 However, this could not cast out the 
possibility that one or more of the selected molecules can also be able to 
bind to other part of the target. 
Thus, herein, I report results of new docking calculations where the search 
area has been enlarged to comprise the entire surface of the quadruplex 
[d(TGGGGT)]4 with the purpose of checking for the capability of the ligands 
to extend their binding out of the groove. Regarding compound 1, docking 
calculations showed that all solutions in the lowest energy families (∆G = -6,2 
kcal mol-1), were found to be anchored to the 3’ side of the groove in line 
with the above-mentioned NMR data (figure 7), compound 1 was predicted 
in a groove binding mode 75 out of 100 time. As shown in figure 8, the amine 
group of compound 1 engages a H-bond with the 4’ O of the T6 nucleoside, 
while the ligand carbonyl group together with the ortho-hydroxyl group of the 
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phenyl moiety forms H-bonds with G5 base. Three H-bonds have been also 
detected between compound 1 and the phosphate backbone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: NMR titrations of compounds 1 with the modified quadruplex A) [d(TGGBrGGT)]4 
and B) [d(TGGGGBrT)]4. 
 
A 
B 
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Figure 8: Binding poses calculated by AD4 for compounds 1 in the quadruplex structure. 
DNA backbone is represented as A) white stick bonds and B) in smooth gold ribbons and 
stick bonds, special filled rings representations are used for the sugars and bases.. Ligands are 
depicted as green sticks. H-bonds are represented as dashed blue lines.  
 
Surprisingly, compound 2 generates almost identical ∆δ values in the titration 
with [d(TGGGGT)]4 and [d(TGGBrGGT)]4 (white and light-grey bars, 
respectively, (figure 9), having a general perturbation of the signals 
belonging to the 3’ side of the groove. 
 
Figure 9: ∆δ values of aromatic (H6/H8), methyl (Me) and imino protons (NH) for 
[d(TGGGGT)]4 (white bars), [d(TGGBrGGT)]4 (light-grey bars) and [d(TGGGGBrT)]4 (dark-grey 
bars). Arrows indicate the lack of bars due to the presence of bromine atoms. 
 
This can be interpreted by assuming that the bromine atom does not affect 
the binding of compound 2 suggesting that it should not preferentially bind 
5’ 
3’ 
A B 
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the very centre of the groove. On the other hand, the titration of 
[d(TGGGGBrT)]4 (dark-grey bars, figure 9) led to a marked shift of T6-H6/Me 
signals whereas only a slight shift of all the other monitored signals can be 
observed. This confirm that compound 2 prefers to interact with the 3’ edge 
of the quadruplex. A clearer picture of the ligand and quadruplex interaction 
could be obtained from docking calculations using again the unmodified 
quadruplex [d(TGGGGT)]4 as target. The calculations highly converged 
towards one family of conformations (∆G = -7.4) (figure 10) in which the 
benzoisoquinolinedione ring stacks on the surface of the 3’ terminal quartet, 
particularly between the T6 and G5 rings, and the rest of the molecule inserts 
into the groove, where the main anchor point is represented by the 
protonated nitrogen of the piperazine ring, which establishes a charge 
reinforced H-bond with the phosphate backbone.  
   
Figure 10: Binding poses calculated by AD4 for compounds 2 in the quadruplex structure. 
DNA backbone is represented as A) white stick bonds and B) in smooth gold ribbons and 
stick bonds, special filled rings representations are used for the sugars and bases.. Ligands are 
depicted as green sticks. H-bonds are represented as dashed blue lines. 
 
This binding mode is consistent with the new NMR titrations (figure 11) 
5’ 
3’ 
A B 
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performed in this investigation indicating that compound 2 is actually 
characterised by a mixed binding mode, providing both stacking and 
groove binding interactions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: NMR titrations of compounds 2 with the modified quadruplex A) [d(TGGBrGGT)]4 
and B) [d(TGGGGBrT)]4. 
A 
B 
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Differently from 1 and 2, titration of compound 3 with [d(TGGGGT)]4, 
[d(TGGBrGGT)]4 and [d(TGGGGBrT)]4 led to a general shift of almost all signals 
(figure 12).  
 
Figure 12: ∆δ values of aromatic (H6/H8), methyl (Me) and imino protons (NH) for 
[d(TGGGGT)]4 (white bars), [d(TGGBrGGT)]4 (light-grey bars) and [d(TGGGGBrT)]4 (dark-grey 
bars). Arrows indicate the lack of bars due to the presence of bromine atoms. 
 
However, the resonances of [d(TGGGGT)]4 (white bars) shifted more and 
those of [d(TGGBrGGT)]4 and [d(TGGGGBrT)]4 less (light- and dark-grey bars, 
respectively). This indicates that compound 3 does not possess a well defined 
binding mode, so that, when the groove is unavailable because of  the 
presence of the bromine atoms, compound 3 slides towards the 3’ edge 
groove of the quadruplex; vice versa, in the case of [d(TGGGGBrT)]4, the 
molecule is able to interact only weakly with the available part of the groove. 
Docking calculations on [d(TGGGGT)]4 suggest that the ligand binds the 3’-
end of the groove (∆G = -8.2) (compound 3 was predicted in a groove 
binding mode 87 out of 100 time). As shown in figure 13, two H-bonds were 
found, the first between the pyridine nitrogen of compound 3 and the T6 3’-
OH group and the second between the hydroxyl group of the chromenone 
core and the G3NH2. 
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Figure 13: Binding poses calculated by AD4 for compounds 3 in the quadruplex structure. 
DNA backbone is represented as A) white stick bonds and B) in smooth gold ribbons and 
stick bonds, special filled rings representations are used for the sugars and bases.. Ligands are 
depicted as green sticks. H-bonds are represented as dashed blue lines. 
 
Hydrophobic contacts between the pyridine and the T6 rings were also 
detected together with a charge reinforced H-bond established by the 
protonated nitrogen of the piperazine ring with the phosphate backbone. 
The same results are confirmed by NMR titration (figure 14).  
 
 
 
 
 
 
 
 
 
A B 
A 
 86 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: NMR titrations of compounds 3 with the modified quadruplex A) [d(TGGBrGGT)]4 
and B) [d(TGGGGBrT)]4. 
 
Interestingly, compound 4 displayed different behaviours for the three 
quadruplexes tested. With the quadruplex [d(TGGBrGGT)]4 (light-grey bars, 
figure 15), the titration provided higher ∆δ values for the residues at the 
edges of the quadruplex with respect to unmodified [d(TGGGGT)]4 (white 
bars, figure 15). On the contrary, titration of [d(TGGGGBrT)]4 caused major 
shift for the residue sitting in the very centre of the groove (dark-grey bars). 
 
  
 
 
 
B 
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Figure 15: ∆δ values of aromatic (H6/H8), methyl (Me) and imino protons (NH) for 
[d(TGGGGT)]4 (white bars), [d(TGGBrGGT)]4 (light-grey bars) and [d(TGGGGBrT)]4 (dark-grey 
bars). Asterisks indicate a severe line broadening of the monitored signals. Arrows indicate 
the lack of bars due to the presence of bromine atoms. 
 
This means that compound 4 can interact with the grooves, and, 
accordingly, when the very centre of the groove is hindered, it binds the end 
sides of the grooves, but it is able to bind the very centre of the grooves when 
their 3’ edges are unavailable. Docking calculations suggest two binding 
poses especially in line with NMR data (figure 16 a, b and c), where the 
molecule can either interact with 5’ residues (binding mode A, ∆G = -8.2) or 
with the 3’ end (binding mode B, ∆G = -7.9).  
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Figure 16: Two binding poses calculated by AD4 for compound 4 A) and B) in the 
quadruplex structure. DNA backbone is represented as white stick bonds, C) in smooth gold 
ribbons and stick bonds, special filled rings representations are used for the sugars and bases 
Ligands are depicted as green sticks. H-bonds are represented as dashed blue lines.. Ligands 
are depicted as green sticks. H-bonds are represented as dashed blue lines. 
 
Specifically, in A, the benzoquinone ring establishes a π-π interaction with the 
T1 ring, while an H-bond between the G2 NH2 group and the carbonyl 
moiety is detected. In B, the two carbonyl moieties of the ligand are 
engaged in H-bonds with G4 NH2 and T6 NH respectively. In both binding 
modes a charge reinforced H-bond is observed between the protonated 
nitrogen of compound 4 and the phosphate backbone. Based on this finding 
and on the shift of NMR signals observed for all residues forming the groove 
(figure 17), a sliding motion of compound 4 inside the groove can be 
proposed. 
 
 
 
A B C 
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Figure 17: NMR titrations of compounds 4 with the modified quadruplex A) [d(TGGBrGGT)]4 
and B) [d(TGGGGBrT)]4. 
 
As far as compound 5 is concerned, the titration of [d(TGGGGT)]4 (figure 18, 
white bars) clearly indicates that compound 5, like the other selected 
A 
B 
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compounds, prefers to bind the 3’ edge of the groove. The titration of 
[d(TGGBrGGT)]4 displays significant lower ∆δ values for the imino protons 
(figure 18, light-grey bars), while the shifts of the signal of G4, G5 and T6 
remain substantially unchanged. 
 
Figure 18: ∆δ values of aromatic (H6/H8), methyl (Me) and imino protons (NH) for 
[d(TGGGGT)]4 (white bars), [d(TGGBrGGT)]4 (light-grey bars) and [d(TGGGGBrT)]4 (dark-grey 
bars). Arrows indicate the lack of bars due to the presence of bromine atoms. 
 
On the other hand, the titration of [d(TGGGGBrT)]4 indicates that compound 5 
is still able to interact with the 3’ edge of the quadruplex probably via end-
stacking interaction. A mixed binding mode is therefore expected for 
compound 5. In line with these data, docking calculations suggested that in 
compound 5 the quinolone ring is adapted on the top of the 3’-end 
sandwiched between the T6 and G5 bases (figure 19), with the imidazo-
pyrimidine moiety extending towards the groove incipience and H-bonding 
with the G5 NH2 group (∆G = -6.7).  
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Figure 19: Binding poses calculated by AD4 for compounds 5 in the quadruplex structure. 
DNA backbone is represented as A) white stick bonds and B) in smooth gold ribbons and 
stick bonds, special filled rings representations are used for the sugars and bases.. Ligands are 
depicted as green sticks. H-bonds are represented as dashed blue lines. 
 
The NMR titration is reported in figure 20.  
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 20: NMR titrations of compounds 5 with the modified quadruplex A) [d(TGGBrGGT)]4 
and B) [d(TGGGGBrT)]4. 
 
Finally, compound 6 displays peculiar titration behaviours. While the titration 
of the unmodified [d(TGGGGT)]4 showed marked shifts of the G2, G3, G4 and 
G5 residues (figure 21, white bars), the titration of [d(TGGBrGGT)]4 is instead 
characterised by very low ∆δ values for all residues (light-grey bars). 
Furthermore, the titration of [d(TGGGGBrT)]4 mainly caused shifts of the 
residues G2, G3 and T6, along with a severe line broadening of the imino 
proton signals (dark-grey bars, figure 21).  
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Figure 21: ∆δ values of aromatic (H6/H8), methyl (Me) and imino protons (NH) for 
[d(TGGGGT)]4 (white bars), [d(TGGBrGGT)]4 (light-grey bars) and [d(TGGGGBrT)]4 (dark-grey 
bars). Asterisks indicate a severe line broadening of the monitored signals. Arrows indicate 
the lack of bars due to the presence of bromine atoms 
 
This means that compound 6 does bind with the grooves of the quadruplex, 
and, as in compound 4, the uniform perturbation of all groove residues of the 
quadruplex [d(TGGGGT)]4, with respect to the limited ligand size, suggests 
that a fast sliding motion of compound 6 inside the groove is also possible. 
Molecular docking calculations also revealed that two molecules of 
compound 6 could in principle simultaneously anchor the two opposite ends 
of the groove although the 5’ end is preferred (42 times out of 100) (figure 22 
a, b and c).  
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Figure 22:  Two binding poses calculated by AD4 for compound 6 A) and B) in the 
quadruplex structure. DNA backbone is represented as white stick bonds, C) in smooth gold 
ribbons and stick bonds, special filled rings representations are used for the sugars and bases 
Ligands are depicted as green sticks. H-bonds are represented as dashed blue lines.. Ligands 
are depicted as green sticks. H-bonds are represented as dashed blue lines. 
 
Notably, in perfect line with the changes experimentally observed for G2 and 
G5 aromatic protons signals, the ligand alternatively forms H-bonds with G2 
(∆G = -7.5) or G5 (∆G = -6.1) bases in the two reported binding modes (figure 
22). Finally, the two poses suggested by the docking program, in which a π-π 
interaction is formed with T1 or T6 ring, could somehow account for the T6-H6 
proton and T1-methyl signals shift. The NMR titration is reported in figure 23.  
 
 
 
 
 
 
A B C 
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Figure 23: NMR titrations of compounds 6 with the modified quadruplex A) [d(TGGBrGGT)]4 
and B) [d(TGGGGBrT)]4. 
 
Isothermal Titration Calorimetry Measurements 
 
In order to determine the binding affinity of the compounds 1-6 with the 
quadruplex [d(TGGGGT)]4, ITC titration experiments were carried out.12 
This kind of study was used in the past also to characterise the interaction of 
Distamycin A with the same quadruplex and it revealed that four molecules 
of the drug were accommodated in two opposite grooves of the 
quadruplex; moreover, the thermodynamic signature of the binding event 
suggested that the entropic contribution was the one driving the complex 
formation.13 An analogous study however was not possible for the six new 
B 
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ligands identified with the virtual screening, because their poor solubility in 
water prevented us from performing canonical ITC experiments,12 in which a 
solution of the quadruplex is titrated with a concentrated drug solution in the 
identical aqueous buffer. 
Nevertheless, an alternative approach to investigate the affinity of the new 
drugs for the DNA quadruplex was carried out by performing 
competition/displacement experiments, by analysing the ability of 
Distamycin A to bind to the quadruplex in the presence of another 
compound.14,15 Despite the solubility concerns, mixtures of the quadruplex 
for each of the six new drugs were successfully prepared by solubilising the 
molecules in DMSO and diluting them in a phosphate solution containing the 
quadruplex; these complexes were then titrated with Distamycin A, and the 
outcome followed by ITC. In figure 24 I report three representative ITC 
experiments.  
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Figure 24: Calorimetric analysis of the interactions of the quadruplex [d(TGGGGT)4] and its 
complexes with the drugs 5 and 6, with Distamycin A. Raw titration data showing the thermal 
effect of injecting Distamycin A into a calorimetric cell containing the quadruplex alone A), 
quadruplex with compound 5 C) and quadruplex with compound 6 E). The normalised heat 
for the titrations, shown in B, D and F respectively, was obtained by integrating the raw data 
and subtracting the heat of the ligand dilution. The heat effect reveals the typical double 
step binding curve of the Distamycin A interaction to the quadruplex in B and C, null 
interaction in F. The red lines in B and D represent the best fit derived by a non-linear least-
squares procedure based on an independent binding sites model.  
 
The titration of Distamycin A with [d(TGGGGT)4] was repeated as control, and 
is clearly shows that in the new experimental conditions this binding event is 
identical to what was previously observed (figure 24, Panels A and B and 
Table 1).  
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The binding occurs in two separate steps, the first one centred on a 
stoichiometry of 1:2 in which two molecules of Distamycin A interact with the 
quadruplex and then a second event in which two more molecules bind, 
leading to a final stoichiometry of 4 molecules of Distamycin A per 
quadruplex. Panels C and E report two displacement experiments carried out 
titrating with Distamycin A the complexes obtained with the drugs 5 and 6 
respectively. The two experiments are quite different and indicative of two 
distinct phenomena. 
In the first case, a binding curve similar to the control experiment is obtained 
(compare figure 24 D and B), indicating that the presence of the drug 5 in 
the mixture did not have an effect on the association of Distamycin A with 
the [d(TGGGGT)4], this means that Distamycin A still binds in two distinct 
events, with stoichiometry and the binding is not significantly affected by the 
presence of compound 5 (Table 1). 
Conversely, the ITC titration of Distamycin A into the quadruplex of the 
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compound 6 complex (figures 24 E and F) gives a completely different 
outcome. In this case, Distamycin A appears no longer able to interact with 
the DNA, suggesting that compound 6 binds to the quadruplex tightly than 
Distamycin A. It is important to highlight that the competition/displacement 
experiments do not give any information about the stoichiometry of the 
complex formed between the quadruplex and the compound competing 
with the Distamycin A. 
A summary of the results for all six compounds is reported in Table 1: 
compounds 1 and 3 behave as compound 5, whereas the presence of 
compounds 2 or 4 or 6 abolishes the binding of Distamycin A. 
In conclusion the competition ITC experiments represent a possible strategy 
to evaluate whether an insoluble groove binder is stronger or weaker than a 
soluble drug that could be used as reference point. In our case, using the 
Distamycin A as reference drug, we were able to group the six drugs 
identified with virtual screening in two extreme classes. The first class contains 
compounds that bind rather weakly to the quadruplex (compounds 1, 3 and 
5), whereas in the second class the drugs that bind substantially stronger than 
Distamycin A (compounds 2, 4 and 6) are clustered. 
This study is very interesting because it proved that the application of Virtual 
Screening calculations together with NMR experiments and Isothermal 
Titration Calorimetry is a successful strategy for the identification of new 
molecular chemo types able to bind the grooves of DNA quadruplex 
structures. The structural diversity of these inhibitors has provided valuable 
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alternative series for on-going lead optimization aimed at the identification of 
brand new pharmacological tools, endowed with better affinity and a 
pharmacokinetic profile and useful in the clarification of the mechanism 
targeting therapeutic potential use of G-quadruplexes. 
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Material and method  
 
Oligonucleotide synthesis 
 
The oligonucleotide d(TGGGGT) was synthesized on a Millipore Cyclone Plus 
DNA synthesizer using solid phase β-cyanoethyl phosphoramidite chemistry at 
15 µmol scale. The oligomer was detached from the support and 
deprotected by treatment with concentrated aqueous ammonia at 55 °C for 
12 h. The combined filtrates and washings were concentrated under 
reduced pressure, redissolved in H2O, analyzed and purified by high-
performance liquid chromatography (HPLC) on a Nucleogel SAX column 
(Macherey–Nagel, 1000-8/46); using buffer A: 20 mM KH2PO4/K2HPO4 aqueous 
solution (pH 7.0), containing 20% (v/v) CH3CN; buffer B: 1 M KCl, 20 mM 
KH2PO4/K2HPO4 aqueous solution (pH 7.0), containing 20% (v/v) CH3CN; a 
linear gradient from 0 to 100% B for 30 min and flow rate 1 ml/min were used. 
The fractions of the oligomer were collected and successively desalted by 
Sep-pak cartridges (C-18). The isolated oligomer proved to be >98% pure by 
NMR. 
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Virtual Screening Calculations 
 
The AutoDock 4.0 (AD4)3,16 software package, as implemented through the 
graphical user interface called AutoDockTools (ADT),7 was used to dock small 
molecules to the G-Quadruplex structure. The DNA file was prepared using 
published coordinates (PDB 1S45).17 Preparation of the DNA and ligand 
structures for docking calculations was attained according to 
parametrization suggested by Neidle and co-workers.18 Thus, point charges 
were assigned to the DNA according to the AMBER94 force field19 and all 
other atom values were generated automatically by ADT. The docking area 
was assigned visually and centred at the N2 nitrogen of the G4 residue in 
chain F. A grid of 22.5 Å x 15.0 Å x 26.25 Å with 0.375 Å spacing was 
calculated around the docking area for 13 ligand atom types using 
AutoGrid17. These atom types were sufficient to describe all atoms in the Life 
Chemicals diversity set database. For VS, compound structures of the 
database were prepared using the ZINC database server 
(http://zinc.docking.org/upload.shtml)20 to take into account the different 
protomeric and tautomeric states of each compound. All the ligands were 
then converted in the AutoDock format file (.pdbqt). For each ligand, 100 
separate docking calculations were performed. Each docking calculation 
consisted of 10 million energy evaluations using the Lamarckian genetic 
algorithm local search (GALS) method. The GALS method evaluates a 
population of possible docking solutions and propagates the most successful 
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individuals from each generation into the subsequent generation of possible 
solutions. A low-frequency local search according to the method of Solis and 
Wets is applied to docking trials to ensure that the final solution represents a 
local minimum. All dockings described in this research were performed with a 
population size of 150, and 300 rounds of Solis and Wets local search were 
applied with a probability of 0.06. 
A mutation rate of 0.02 and a crossover rate of 0.8 were used to generate 
new docking trials for subsequent generations, and the best individual from 
each generation was propagated to the next generation. The docking results 
from each of the eight calculations were clustered on the basis of root-
meansquare deviation (rmsd) between the Cartesian coordinates of the 
atoms and were ranked on the basis of free energy of binding. The top-
ranked compounds were visually inspected for good chemical geometry. 
Pictures of the modelled ligand/enzyme complexes were rendered with UCSF 
Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco.21 
 
Nuclear magnetic resonance experiments 
 
30 NMR samples were prepared at a concentration of 1.7 mM, in 0.2 ml 
(H2O/D2O 9:1) buffer solution having 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA, 
pH 7.0. NMR spectra were recorded with Varian UnityINOVA 700 MHz 
spectrometer. 1H chemical shifts were referenced relative to external sodium 
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2,2-dimethyl-2-silapentane-5-sulfonate (DSS). 1D proton spectra were 
recorded using pulsed-field gradient DPFGSE10,11 for H2O suppression. 
All 30 tested compounds were checked before titration by NMR and mass 
spectrometry. All samples turned out to be >95% pure. 
The stability of [d(TGGGGT)]4 in DMSO was tested by adding progressively 
deuterated DMSO in 2.0 mM concentration of quadruplex (0.5 ml H2O/D2O 
9:1 buffer solution having 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA, at pH 7.0). 
After each addition of DMSO-d6, the quadruplex was checked by 1D 1H NMR 
experiments. 
DMSO was added up to an overall percentage of 30%. At this stage we were 
able to still observe the four imino resonances, that are very diagnostic of the 
presence of the quadruplex.  
Phasesensitive NOESY spectra22 were recorded with mixing times of 100 and 
200 ms (T = 25 °C). Pulsed-field gradient DPFGSE10,11 sequence was used for 
NOESY experiments in H2O. 
NOESY experiments were recorded using STATES-TPPI23 procedure for 
quadrature detection. The time domain data consisted of 2048 complex 
points in t2 and 400 fids in t1 dimension. A relaxation delay of 1.2 s was used. 
The NMR data were processed on iMAC running iNMR software 
(www.inmr.net). 
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Molecular modelling 
 
The binding modes of compounds 1-6 were studied by means of docking 
experiments with the aid of Autodock4 (AD4)3,24 and using the [d(TGGGGT)]4 
G-quadruplex DNA structure as deposited in the Protein Data Bank (PDB 
code 1S45) as macromolecules. The 3D structures of all the compounds were 
generated with the Maestro Build Panel.25 For the purpose of docking each 
molecule has been constructed in the protonation state suggested by the 
MarvinSketch 5.2.5.1 package (http://www.chemaxon.com) using a pH 7.0 
accordingly with the NMR titrations. The target DNA structures were prepared 
through the Protein Preparation Wizard of the graphical user interface 
Maestro 9.0.2116 and the OPLS-2001 force field. Water molecules were 
removed, hydrogen atoms were added and minimisation was performed 
until the RMSD of all heavy atoms was within 0.3 Å of the crystallographically 
determined positions. Then the constructed compounds and DNA structures 
were converted to AD4 format files using ADT generating automatically all 
other atom values. In order to allow the ligands to explore all the possible 
search space, the docking area has been centred on the mass centre of the 
quadruplex structure and defined by a box large enough to comprise the 
entire macromolecule. 
Accordingly, grids points of 84× 84×84 with 0.375 Å spacing were calculated 
around the docking area for all the ligand atom types using AutoGrid4. 100 
separate docking calculations were performed for each binder. Each 
 106 
 
docking calculation consisted of 25×106 energy evaluations using the 
Lamarckian genetic algorithm local search (GALS) method. A low-frequency 
local search according to the method of Solis and Wets was applied to 
docking trials to ensure that the final solution represents a local minimum. 
Each docking run was performed with a population size of 150, and 300 
rounds of Solis and Wets local search were applied with a probability of 0.06. 
A mutation rate of 0.02 and a crossover rate of 0.8 were used to generate 
new docking trials for subsequent generations. The docking results from each 
of the 100 calculations were clustered on the basis of root-mean square 
deviation (RMSD 2.0 Å) between the Cartesian coordinates of the ligand 
atoms and were ranked on the basis of the free energy of binding. All 
docking solutions were analysed for the coherency with NMR data and for 
each compound, the lowest energy solution more in line with the 
experimental data was further considered and subjected to energy 
minimisation through the OPLS-2001 force field. All figures were rendered 
using Chimera software package.26 
 
Isothermal titration calorimetry 
 
The [d(TGGGGT)4] stock solution was prepared by dissolving the lyophilised 
compound in 10 mM phosphate buffer with 70 mM KCl, 0.2 mM EDTA, pH 7. 
The solution was annealed by heating at 95 °C for 5 min and slowly cooling to 
room temperature. The concentration of the dissolved oligonucleotide was 
 107 
 
evaluated by UV measurement at 95 °C, using as molar extinction coefficient 
the value calculated by the nearest-neighbour model27 for the sequence 
d(TGGGGT). Stock solutions of the six drugs were prepared by solubilising 
weighted amounts in DMSO to a final concentration of 8 mM. The complexes 
between the quadruplex and the drugs were prepared diluting the drug 
stock solution into the quadruplex solution to get a final DNA:drug molar ratio 
of 1:4.1 and a final DMSO concentration of 7%. Distamycin A was solubilised in 
the same buffer used for the oligonucleotide containing 7% of DMSO. 
The titrations were carried out in 10 mM phosphate buffer, 70 mM, KCl, 0.2 
mM EDTA, 7% DMSO, pH 7, at 293 K, using a high sensitivity ITC-200 
microcalorimeter from Microcal (GE Healthcare). In each experiment, 
volumes of 2 mL of a 1.2mM Distamycin A solution were added into a 50 mM 
solution of quadruplex-DNA complex, using a computer-controlled 40-mL 
microsyringe, with a spacing of 180 s between each injection. Each titration 
was corrected for heat of dilution by subtracting the measured enthalpies of 
the injections following saturation. Integrated heat data obtained for the 
titrations were fitted using a non-linear least-squares minimisation algorithm to 
a theoretical titration curve, using the MicroCal-Origin 7.0 software package 
from which the binding parameters ∆H° (reaction enthalpy change in kcal 
mol-1), Kb (binding constant in M-1), and n (stoichiometry) were derived. The 
entropic contribution was calculated using the relationships ∆G° = -RT·lnKb (R 
1.987 cal mol-1 K-1, T 293 K) and ∆G° = ∆H°-T∆S°. 
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“Fine tuning” of the selected compounds 
 
In order to improve the binding affinity of the selected compounds we have 
also performed Similarity Search. Herein, I report some preliminary results 
about the structural optimization performed on compound 6, who showed 
the more promising results. 
The rationale of this new approach is that we calculate the degree of 
similarity between the control compound and all the molecules present in a 
given databases; this value of similarity is measured with the Tanimoto index 
(T index) who can assume values between 0 (for molecules without a degree 
of similarity) and 1 (for molecules structurally identical to the reference 
compound). 
In our case, the entire database ZINC8, having more than thirteen million 
compounds, and a T index = 0.8 (that means to consider 80% of similarity) 
have been used. In this way, we have found 61 new compounds that have in 
common with compound 6 the scaffold 2H-cromen-2-ones. Also in this case 
we have performed NMR titration for all compounds to evaluate the binding 
mode with the DNA quadruplex and we used the NMR data to draw a 
structure-activity relationship (SAR), in order to understand which part of the 
drug is important for a strong interaction with the quadruplex and which part 
do not permit the interaction. We have found 16 (figure 1) molecules that 
present a good affinity for the quadruplex, and for all was done a biological 
study to evaluate if these compounds cause a DNA damage. 
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Figure 1: The 16 compounds founded, they have cumarine and chromone structures. 
 
All the selected compounds were also tested from a biological point of view. 
In particular, human transformed fibroblasts (BJ-EHLT) were exposed to 
different concentrations (doses 0.1 and 0.5 µM) of each compounds for 24 
hours and activation of damage response was measured by 
immunofluorescence (IF) (figure 2) using antibodies against γ-H2AX and TRF1 
to mark DNA damage and telomeres respectively. 
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Figure 2: Analysis of DNA damage response activation at telomeres by different ligands. BJ-
EHLT fibroblasts were treated for 24 hrs with the doses 0.1 and 0.5 µM of Dystamicin A (Dys) 
and ligands from G1 to G16. Cells were processed for immunofluorescence (IF) using 
antibodies against γH2AX and TRF1 to mark DNA and telomeres damage, respectively. 
Percentage of γH2AX- A) and TIF-positive cells B) in untreated and cells exposed to the 
indicated treatments. Cells with four or more γH2AX/TRF1 foci were scored as TIF positive. 
Mean number of γH2AX/TRF1 C) foci in the indicated samples. Three independent 
experiments were evaluated, and error bars indicate the standard deviation. D) 
Representative images of IF from γH2AX/TRF1 staining of untreated and Dys A, G2, G3, G4-
treated BJ-EHLT fibroblasts are shown. Enlarged views are reported below the merged 
images from the samples treated with the G-ligands which have induced the highest 
percentage of TIF positive cells among all the compounds analyzed in (B). The images were 
acquired with a Leica Deconvolution microscope (magnification 100x).  
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It is noteworthy that the cells treated with the compounds from G1 to G4 (G1 
was formerly named compound 6) induced strong phosphorylation of γ-
H2AX, and this confirms that these compounds are DNA damage inducers 
(figure 2A). The four more active compounds (G1-G4) were also tested in 
order to clarify whether the damage could be localized at telomere level. 
Very interestingly, they were able to induce only telomeric damage (TIFs - 
telomere dysfunction-induced foci) (see figure 2B). The average number of 
TIFs per nucleus are visible in figure 2C. Cell with four or more γH2AX/TRF1 foci 
were scored as TIF positive.  
In order to verify whether γ-H2AX was phosphorylated in response to 
dysfunctional telomeres, a deconvolution microscopy has been performed, 
that revealed that some of the damage foci induced by the compounds 
G2,G3,G4 colocalized with TRF1, an effective marker for interphase telomeres 
(figure 2D). 1,2  
We analyzed also the biological effect of treatment with G2 (the compound 
displaying better results) on HeLa cells. This drug is clearly capable to induce 
the tumor cell death in HeLa cells to different doses (figure 3A) and it is also 
capable to block the cell cycle in G0-G1 phase (figure 3B), that means we 
have a cellular death for apoptosis. The SA-b-gal activity (Senescence-
associated-β-Galactosidase Staining) was also tested, and it showed (figure 
3C) the presence of some cells in senescence.  
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Figure 3: Biological effects of treatment with G2 ligand. A) Survival curve of the HeLa cells 
exposed to different doses of G2 ligand ranging from 0.5 to 5 µM. Surviving fractions were 
calculated as the ratio of absolute survival of the treated sample/absolute survival of the 
control sample. The data represent the mean of four independent experiments with 
standard deviations (SD). B) Cell cycle analysis of HeLa cells untreated or treated with 2 and 
5 µM G2 ligand. Cells were processed 5 days after G2 exposure. y axis, cell numbers; x axis, 
relative DNA content on the basis of staining with propidium iodide. The percentages of the 
different cell cycle phases reported in the bar graph were calculated by the ModFit LT 
software. C) The induction of senescence was evaluated by the SA-β-gal staining of Hela 
cells untreated and treated with 5 µM G2 ligand for 5 days. A representative of three 
independent experiments with comparable results is shown. Original magnification, 40x. 
 
These interesting results need to be validated by in vivo experimental models 
of human cancers. In particular, the evaluation of toxicological profile and 
anticancer activity of this promising new groove binders (figure 4) will allow us 
to assess its therapeutic index and to proceed along the development 
process to future clinical applications. 
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Composto 6 (G1)    Composto G2 
 
                           
         
                        Composto G3                Composto G4 
Figure 4: The new groove binders. 
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Conclusions 
 
A successful structure-based virtual screening (VS) campaign was recently 
undertaken by our research group and it resulted in the identification of six 
small molecules able to interact with the groove of the quadruplex 
[d(TGGGGT)]4. 
In this dissertation, I have reported NMR spectroscopy experiments which, 
combined with extensive molecular docking studies, allow for a more 
detailed picture of the interaction between each VS-derived binder and the 
quadruplex DNA. Noteworthy, Isothermal Titration Calorimetry (ITC) 
measurements revealed that compounds 2, 4, and 6, despite their relatively 
small dimensions, bind substantially stronger than Distamycin A, which is, to 
the best of our knowledge, the most potent groove binder identified so far. 
As it is widely accepted that specificity among the various DNA G-
quadruplexes, that might be simultaneously present in the human genome, is 
a fundamental requirement for the quadruplex binder to become a drug, 
extensive binding tests towards DNA duplex and different DNA quadruplex 
topologies will be the next step in our research program. The future results 
from the combination of a different approaches with structural studies will 
provide a source of inspiration for the design of next generation of potent 
and selective quadruplexDNAdrug-like binders. 
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CHAPTER III  
 
La Protein 
 
The La protein is a monomeric phosphorprotein that can be found in the 
nucleus of eukaryotic cells. The La protein was first discovered as an 
autoantigen found in patients suffering from the rheumatic diseases systemic 
lupus erythematosus and Sjogren’s syndrome.1, 2  
Although La was first characterized as a human protein, homologs have 
been identified in a wide variety of eukaryotes.3–12  
A lot of experiments revealed that the La protein is associated with a very 
large number of nascent small RNAs for example: pre-tRNAs, pre-5S rRNA, U6 
small nuclear RNA (snRNA), RNase P RNA, MRP RNA, 7SL RNA, Y RNAs, rodent 
4.5SI and 4.5SII RNAs, and transcripts of Alu sequences.13–20 
Others experiments revealed that La also binds a number of viral-encoded 
RNAs, including the adenovirus-encoded VA RNAI and VA RNAII,13, 21 the 
Epstein-Barr virus–encoded EBER 1 and EBER 2 RNAs,22 and the leader RNAs of 
several negative-strand viruses.23–26 
For the majority of cellular RNAs, La binds the precursors, rather than the 
mature RNAs. For instance the U6 RNAs, bound by the human La protein, are 
extended at the 3’-end and contain fewer modifications than the mature 
RNA.20 Similarly, the La protein binds precursors to tRNAs and 5S rRNA, but 
does not bind the corresponding mature RNAs.15  
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The reason why the La protein associates primarily with nascent RNA 
polymerase III transcripts became clear when it was shown that at least part 
of the recognition site for the protein is UUUOH, which is at 3’ end of virtually all 
newly synthesized RNA polymerase III transcripts.27–29 These terminal uridylates 
are usually removed during RNA maturation, thus eliminating the binding site 
for the La protein. Consistent with this, the yeast La protein also binds certain 
nascent RNA polymerase II–transcribed small RNAs that end in UUUOH.30, 31 
In most cases, the 3’-end binding of the La protein is only transient, the 
protein being displaced upon excision or modification of the 3’-UUUOH motif. 
So far, the best-established role of the La protein is to provide protection 
against 3’-exonucleolytic degradation with various consequences 
depending on the nature of the transcript. 
For pre-tRNAs and pre-U3 snRNA, La protein binding allows normal processing 
of the RNA.31, 32 The La protein was also shown to exhibit an RNA chaperone 
activity,33 promoting correct folding of certain pre-tRNAs34 or facilitating the 
assembly of U snRNAs into functional ribonucleoprotein particles.30, 35 As a 
consequence of these activities the La protein most probably takes part in 
the quality-control mechanism of newly synthesized noncoding RNAs.36-38 In 
addition genuine La proteins are versatile factors that were reported in 
yeasts, flies, and mammals to bind to certain mRNAs and to influence their 
translation efficiency,39-44 their stability, or subcellular localization;45-47 many 
reports established that the HsLa (human genuine La) protein directly binds to 
several viral RNAs, often enhancing their translation and replication 
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efficiency48-52 and, at least for some viruses, shielding them from the host’s 
defence systems.52  
In general, most mRNAs for which La positively effects translation have 
lengthy and complex 5′ UTRs, whereas studies of specific mRNAs whose 
outcomes revealed a negative effect on translation were on mRNAs with 
short presumably nonstructured 5′ UTRs such as the very short 5′ UTR 
containing 5′TOP mRNAs.53,54-56 In this regard, it is relevated that the 
nonphosphorylated (cytoplasmic) isoform of the human La protein can 
recognize the 5′ GpppN cap (and related structures) present on cellular 
mRNAs.57  
Binding to the caps of 5′ TOP mRNAs by nonphospho-La may inhibit cap-
mediated translation initiation. The same activity on complex, e.g., IRES 
mRNAs can conceivably shift the balance toward internal initiation. This 
would not necessarily exclude a more direct role for La at the IRES element 
(HCV mRNA) itself or just upstream of the AUG, as for MDM2 mRNA.42  
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Structural analysis of La proteins 
 
Alignment of La proteins from species ranging from humans to trypanosomes 
reveals that these proteins can be divided into at least three regions (figure 
1). The N-terminus of all known La proteins contains the ~60 amino acid and 
this is called La motif, a highly conserved sequence that is also present in a 
number of otherwise unrelated proteins.7,58,59,60 Following the La motif, there is 
a less well conserved RNA recognition motif, called RRM (RNA Recognition 
Motif),61,62 and a highly charged, weakly conserved C-terminus. Consistent 
with the idea that the C-terminus represents a distinct domain of La, this 
portion of the human protein can be severed from the N-terminal half of the 
protein by a variety of proteases.4,63 The molecular size of the La protein 
varies from ~50 kilodaltons in vertebrates to 32 kilodaltons in the yeast S. 
cerevisiae (figure 1). Almost all of the additional mass of the larger La proteins 
is due to an expanded C-terminal domain (figure 1). 
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Figure 1: Structure of La proteins. The human, Drosophila, C. elegans, S. pombe, S. 
cerevisiae, and T. brucei proteins are aligned. For each protein, the length in amino acids is 
indicated on the right.  
 
The C-terminal domain is the least conserved part of the La protein, varying in 
both size and sequence between species. With the exception of genuine La 
homologs from a few species,64,65 the COOH-terminal domain (CTD) of 
genuine La proteins contains the atypical RRM (RRM2) followed by an 
unstructured terminal region that contain several phosphorylation sites, a 
short basic motif (SBM), a nuclear localization signal (NLS), and a nuclear 
retention element (NRE) 10,66-69 (figure 1). Disruption of these trafficking 
elements causes mislocalization of La and malfunction in tRNA maturation, 
and in some cases leads to disorder of some of the pre-tRNA processing 
steps.70,71 
Metabolic labeling experiments have revealed that La proteins from humans 
H. sapiens La 
 
D. melanogaster La 
 
C. elegans C44E4.4 
 
S. pombe Sla1 
 
S. cerevisiae Lhp1p 
 
T. brucei La 
 
408 
390 
395 
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335 
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to yeast are phosphorylated in vivo.10,72,73 The human La protein is 
phosphorylated at multiple sites, all of which appear to be located within the 
C-terminal domain.63,71,72 To date, four phosphorylation sites have been 
mapped in the human protein. The major site of phosphorylation is a casein 
kinase II site at Ser 366.73,74 In addition, the protein is phosphorylated at Thr 
302, Ser 325, and Thr 362.74 On the basis of sequence comparison, none of 
these sites appear conserved beyond vertebrate La proteins. Consistent with 
a lack of conservation, the major sites of phosphorylation were recently 
mapped in the S. cerevisiae La protein. Two of the three major sites of 
phosphorylation map to the N-terminus of the protein, and the major C-
terminal site does not correspond to a casein kinase site.75 
In the past the structure of the La motif has been debated, because some 
predicted that it folded as a canonical RRM, others contended that it 
adopted a predominantly helical configuration;64,68,76 but all doubts were 
resolved with a work of Alfano et al.77 where an NMR study resolved the 
structure of both domains: La Motif and RRM1 (figure 2). 
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Figure 2: Secondary structure of La Motif, central RRM (RRM1) and C-terminal RRM2 of La 
genuine protein. (Taken from Alfano et al.77). 
 
They have demonstrated that the La Motif does not adopt an RRM-like fold, 
as was proposed in the past, but its compact structure comprises six α-helices 
and a three-stranded antiparallel β-sheet78-80 (figure 2). The structure of the La 
motif is dominated by a very long amphipathic α-helix (α1), which is followed 
by a shorter helix labeled α1’. The polar flank of helix α1 is largely solvent 
exposed but the opposite apolar face makes hydrophobic contacts with 
every other secondary structure element in the La Motif, forming the 
hydrophobic core of the domain. The twisted three-strand β-sheet 
contributes apolar residues to the domain core but also presents a solvent-
exposed surface on the opposite side of the domain to helix α1. The C-
terminal extension of strand β3 contains a well-defined loop followed by an 
extended arm that folds back onto the molecule, contacting helix α1’ and 
the loops connecting it to α1 and α2 (figure 2). 
La Motif RRM1    RRM2 
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RRM1 (figure 2) has a classical RRM structure consisting of a four-strand β-
sheet backed by two α-helices but has an unusual C-terminal α-helix that 
projects up from the β-sheet RNA-binding surface. Helix α3 is predominantly 
hydrophilic and protrudes away from the body of the domain and toward 
the solvent. This configuration is also in marked contrast to the long, 
amphipathic helix α3 of the RRM2 of hLa, which forms an extensive network 
of hydrophobic interactions with an apolar patch on the β-sheet, thereby 
obscuring the putative RNA-binding surface81 (figure 2). Thus the β-sheet 
surface of the RRM1 seems to be largely available for RNA interactions.  
This NMR study has demonstrated that the La Motif and RRM1 are 
independently folded and maintain the same three-dimensional structure in 
the context of an NTD fragment. It was also confirmed that the two domains 
act synergistically in the RNA binding because when they are present in 
isolation, neither La Motif nor the RRM1 has affinity for oligo (U) RNA. 
Whilst the conserved NTD of La binds to 3’-UUUOH sequences common to pol 
III transcripts and other small RNAs, for the CTD the role in RNA binding is less 
well characterized, but it appears to have a distinct role in RNA recognition 
and is reported to be involved in binding 5’-triphosphates and internal 
sequences in structured RNA molecules.57,64,68,82-85 Moreover, the CTD has 
been proposed to play a role in pol III reinitiation, although the involvement 
of La in transcription termination and the regulation of recycling of pol III 
transcription complexes is still controversial.64,68  
In the 2003 Jacks et al.81 resolved the structure of the RRM2 (figure 2).  
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This RRM2 has a different structure from canonical RRMs, in fact it possesses a 
β1-α1- β2- β3- α2- β4’- β4- α3 topology and folds to generate a five stranded, 
antiparallel β-sheet that is terminated by a long α helix which obscured the 
RNA binding surface. Until recently, it seemed that the RRM2 domain did not 
display the ability to bind RNA,81 although several reports suggested that the 
C-terminal domain is involved in the regulation of the complex nuclear and 
cytoplasmic activities of genuine La proteins, at least in mammals.86 
We know that the La protein binds specifically to the 3’ polyU ends 
characteristic of most Pol III precursors, but in the 2011 Martino L. et al.87 have 
demonstrated that La is capable to bind to several viral RNAs. They studied 
the binding to the Hepatitis C Virus (HCV) genome in the stem-loop IV of the 
IRES domain (Internal Ribosomal Entry Site). By systematic biophysical 
investigations, they have discovered that La binds to domain IV using an RNA 
recognition mechanism that is quite distinct from its mode of binding to RNAs 
with a 3’ UUUOH trailer: although the La Motif and first RNA recognition motif 
(RRM1) are sufficient for high-affinity binding to 3’ oligoU, recognition of HCV 
domain IV requires the La Motif and RRM1 to work in concert with the 
atypical RRM2 which has not previously been shown to have a significant role 
in RNA binding. This new mode of binding does not appear sequence 
specific, but recognizes structural features of the RNA, in particular a double-
stranded stem flanked by single stranded extensions. 
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Poly-U binding of La protein 
 
Previous studies have established that both domains, the La Motif and RRM1, 
were required for recognition of 3′-UUUOH by La;85,88 a co-crystal structure 
containing the La domain from human La (hLa) and a short RNA ending in 
UUU-3′OH revealed that this mode of binding surprisingly occurs through 
contacts other than to the expected surfaces,89 but nonetheless confirming 
the requirement for both motifs for RNA binding (figure 3). Furthermore this co-
crystal structure analysis has highlighted that the linker polypeptide 
connecting the two domains fold into an α helix when there is an RNA binds, 
this appears to be an indirect effect of RNA binding because there are no 
contacts between the RNA and this portion of the polypeptide.89 
 
Figure 3: A co-crystal structure of binding modes of the La motif and RRM1 of the human La 
protein (NTD) with AUAAUUU RNA bound. La motif is in orange; interdomain linker in green 
and RRM1 in brown. (Taken from Kotik-Kogan et al. 2008.89) 
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To explain the binding mode of La protein Kotik-Kogan et al.89 have made 
NMR and crystal studies with different RNA oligomers ended with 3’-UUUOH; in 
particular they studied the following oligos: AUUUU, AUAAUUU, 
AUAUUUU,UUUUUUUU for the crystal structures, whilst for the NMR study they 
used UU, UUU, UUUU, UCUU, AUUUU, UUUUUUUU RNA oligomers. 
The crystal structure of the complex LaNTD: AUUUU revealed a number of 
important structural details of the recognition of the 3′ end of the RNA 
oligomer that help to explain the specificity of the LaNTD for sequences 
terminating in UUUOH. The major interactions are made by the terminal pair 
of nucleotides (U−1/U−2), which consistently make the closest contacts with 
the protein and appear to provide the majority of the binding energy for the 
interaction (figure 4).  
 
Figure 4: Structure of the LaNTD:AUUUU complex showing just the last two nucleotides, U
−
1 
and U
−
2. The RNA is shown as a stick model. The protein is colored by domain: La Motif 
orange and RRM1 brown; selected side chains are shown as sticks with their carbon atoms 
colored by domain. Hydrogen bonds are shown as dashed lines. (Taken from Kotik-Kogan et 
al. 2008.89) 
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The NMR studies have outlined that very similar patterns of chemical shift 
perturbation were observed in all classes, consistent with a common mode of 
3’ end recognition that involves both the La Motif and RRM1 domains and 
appears largely dominated by the interactions made by the last two 
nucleotides in the sequence, U-1 and U-2, as found in all crystal structures. 
U−1 interacts exclusively with the La motif (figure 4), specific H-bond 
interactions between U−1 and the La motif only involve backbone features of 
the nucleotide: the 2’ and 3’ OH groups from the ribose ring of U−1 are 
specifically recognized by hydrogen bonds to the O atoms of the side-chain 
carboxylate moiety of D33 (figure 4), additionally, the O1 atom of the U−1 
phosphate group makes hydrogen bonds with both the backbone NH groups 
of N56 and R57 and with the side-chain OH of Y24. Consistent with the 
structure, these interactions with the ribose-phosphate backbone have been 
shown by mutagenesis to be important for 3’ end recognition.79,90 The 
penultimate nucleotide, U−2, makes intimate contacts with the protein that 
involve both the La motif and RRM1 (figure 4). In contrast to U−1, it is the 
nucleotide base of U−2 and not its backbone that makes specific hydrogen 
bonds to the protein. Atoms O2 and O4 from the pyrimidine ring of U−2 
hydrogen bond to the side-chain amide of Q20 (La motif) and the main-
chain amide of I140 (RRM1), respectively, a pair of interactions that clearly 
helps to draw the two domains together. The pyrimidine ring of U−2 is also 
stacked directly on top of Y23, a residue from the La motif that is positioned 
by a hydrogen bond from the tyrosine side chain to the side chain of N139 of 
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RRM1, which in turn stacks on top of F28 from the La motif (figure 4). The U−2 
pyrimidine ring is also packed directly underneath L124 from RRM1, a residue 
that is at least partly secured in place by the salt bridge made by its neighbor 
(D125) with R57 from the La motif.  
Thus, the recognition of U−2 in the complex engages a concerted set of 
protein:RNA and protein:protein interactions involving residues from both 
domains to form a tightly defined pocket that is specific in size, shape, and 
hydrogen-bonding capacity for a uridylate base; NMR analyses confirm that 
these interdomain interactions only form upon RNA binding. This induced fit of 
the binding pocket around U−2 accounts well for the cooperative nature of 
RNA binding by both domains of LaNTD.76,77,79,85  
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CHAPTER IV 
 
La-related proteins (LARPs) 
 
The La Module (La Motif plus RRM1) is also present on proteins otherwise 
unrelated to genuine La, referred to as La-related proteins (LARPs).1-11 
Contrary to the well characterized genuine La protein, functional and 
structural data on LARPs are very scarce, and to date only a few LARPs have 
been characterized.  
Phylogenetic analyses, together with structural motif searches allowed us to 
propose that besides the genuine La proteins family, LARPs can be divided 
into four clearly distinct families (LARP1, 4, 6, and 7). The greatest degree of 
homology between these various LARP classes of proteins occurs in the La 
Motif and also the RRM1 (figure 1). 
 
Figure 1: Schematic alignment indicating the conserved La Motif–RRM domain architecture 
of the genuine La proteins followed by LARPs (Taken from Bayfield Mark A. et al.13).  
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Initially, because of their similarity to La genuine protein, the researchers 
thought that LARPs also had same features of binding, in other words that 
they were capable to bind ligand with UUU-3′OH ended, but this has not 
always proved true. In fact, whereas some LARPs are indeed capable to 
recognize the RNA ending with the UUU-3′OH like the genuine La protein, 
LARP4 shows a different mechanism of recognition in that instead of binding 
poly (U) RNA it binds poly (A) RNA.  
In humans two LARP4 family members are found (hLARP4 and hLARP4b, 
previously called hLARP5),12 which share 37% identity and 53% similarity 
throughout their amino acid sequence. Unlike other LARPs, LARP4 and 
LARP4b diverge in several of the amino acids critical for canonical UUU-3′OH 
recognition, suggesting that, as already outlined, that the LARP4 family is the 
most diverged from genuine La proteins and other LARPs in the RNA binding 
pockets of their La Module.13 
 
Role of LARP4 
 
In 2010 the Conte’s group at King’s College in collaboration with others, have 
discovered the role and functions of LARP4.14 
Using several techniques as Nuclear Magnetic resonance (NMR), 
crystallography, Isothermal Titration Calorimetry (ITC), researchers have found 
that LARP4 can bind poly(A) RNA via the La Module and interacts with the 
MLLE domain of poly (A) binding protein (PABP) via a non-canonical PAM2 
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sequence.  
This discovery is very important because, contrary to what it was previously 
believed (that the two domains, La Motif and RRM, of LARPs protein such as 
in the La genuine protein, work together to bind the RNA ligands ending in 
UUU-3’OH) it is now clear that instead LARP4 binds poly-A RNA, and this 
different interaction involves in a different function. In fact the protein LARP4 
binding the poly (A) RNA present at the 3’ untranslated region (UTR) of most 
mRNAs, stabilising it and therefore stimulating translation.  
Biophysical and nuclear magnetic resonance (NMR) studies have shown that 
a peptide representing LARP4 PAM2w interacts with the MLLE of PABP with a 
Kd within the range found for other PAM2 motifs. This is significant, because it 
suggests that LARP4 (and probably LARP5/4b) functions as parts of a network 
of proteins that compete for the PABP MLLE domain.  
This PAM2w differs from all other known PAM2 sequences in that it contains a 
Trp in place of Phe, the latter being the most important contributor to MLLE 
binding15 and this study showed that this mutation did not affect the overall 
binding affinity to MLLE PABP.  
The interaction of LARP4 with the RNA has been investigated by EMSA assays, 
where the binding properties of the La modules from of human La(1-235) and 
LARP4(1-286) have been compared. Among the homopolymers tested, A(20) 
exhibited the best affinity for LARP4-NTD, as reflected by the ratio of free to 
bound RNA, whereas U(20) showed less binding and C(20) and G(20) showed 
no binding (figures 2 A to D).  
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Figure 2: EMSA of homopolymeric 20-mer RNAs for binding to the RNA binding domain of 
LARP4 protein. (Taken from Yang R. et al.14 ) 
 
LARP4 binding to RNA was not affected by addition of 3’ phosphate; this is a 
difference with La protein that is capable to bind only ssRNA ending with 3’ 
hydroxyl (figure 3). 
 
Figure 3: Comparison of LARP4(1-286) binding to otherwise identical 36-mer RNAs that end 
with a 3’-OH or a 3’-phosphate. (Taken from Yang R. et al.14 )  
 
ITC (figure 4) was employed to study in more detail the RNA binding 
properties of La Motif-RRM of LARP4. The interaction of LARP4 (111-303) with 
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three different RNAs was tested. This study confirmed that LARP4 is not 
capable to bind to short RNAs, and that it only binds to poly (A) and not poly 
(U) RNAs. In fact as shown in panels below, it binds to poly A15 (see panel A) 
but not poly A10 (see panel C) indicating a requirement for a specific length 
of its RNA target. This is a specific feature that differs from the binding profile 
of genuine La protein. 
 
Figures 4: (A to C) Isothermal titration calorimetric analysis of LARP4(111-303) interactions 
with A(15), U(15), and A(10). The Kd and other thermodynamic parameters derived from this 
analysis are reported in Table 1. (Taken from Yang R. et al.14 ) 
 
TABLE 1. Thermodynamic parameters of the interaction of La(1-194) and LARP4(111-303) with 
single-stranded RNA sequencea 
 
a The values represent the averages and the standard deviations over three independent 
measurements. 
 
The titration analysis of LARP4(111-303) with A(15), has shown that binding 
occurs as one event centred on a molar ratio of 1. LARP4(111-303) interacts 
A B C 
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with A(15) with a Kd of 714 nM, with entropically driven binding (Table 1). In 
contrast, LARP4(111-303) displayed very weak association with U(15) and 
A(10) with a Kd beyond the threshold that could be rigorously measured by 
ITC, i.e., ≥0.1 mM. Therefore, LARP4 binds to A(15) at least 200-fold more tightly 
than U(15) and A(10). 
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CHAPTER V 
 
Materials and Methods 
 
My project concentrated on the study of the structure of the two domains of 
LARP4: La Motif 111-196 and RRM 196-287.  
Before studying the NMR spectra, I expressed protein in bacteria system, so I 
have learnt how to purify the proteins.  
In this chapter, I will illustrate the different protocols that I have applied to 
express and to purify the protein, in order to obtain a good NMR sample. 
 
Plasmid and bacterial cell strains used in this study 
 
The two domain of LARP4: La Motif(111-196) and RRM(196-287) were cloned 
in Conte’s laboratory in a pET-Duet-1 expression vector and expressed in 
E.Coli Rosetta II cells. 
 
Transformation of competent cells  
 
The competent cell (BL21 Rosetta from Novagen) was taken and 1 µl of 
required plasmid DNA was added in a sterile Eppendorf tube. The mixture 
was then left on ice for 30 minutes. After that the cells were “heat shocked” 
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at 42°C for 30 seconds and put in the ice for further 2 minutes. After that 250 
µl of LB were added followed by incubation at 37°C for 1 hour. An aliquot 
(100 µl) of transformed cells was spread onto an LB agar plate containing the 
proper antibiotic (0.100 mg/ml Amplicillin and 34 mg/ml Chloramphenicol), 
and incubated at 37°C. 
 
Expression studies 
 
A single colony was inoculated in 10 ml of LB media supplemented with 
antibiotics, like Ampicillin and Chloramphenicol, as appropriate, and grown 
to an OD600 of 0.6. Next, isopropyl-β-D-thiogalactopyronoside (IPTG) was 
added to a final concentration of 1 mM so as to induce production of the 
desired protein. The cultures were grown for a further 3 hours at 37°C before 
harvesting by centrifugation (3000 x g/10 minutes at 4°C).  
 
Large scale expression of unlabelled protein 
 
Cells previously tested for protein expression were then grown at 37°C 
overnight in 100 ml of LB medium and on the day after diluted in 2L of LB 
medium containing antibiotics before being incubated at 37°C at 220 rpm. 
When the OD600 reached values around 0.6, the protein expression was 
induced for 3 hours with 100 µg/ml of IPTG. In the next stage the cells were 
harvested at 7000 rpm for 20 minutes and frozen until further use. 
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Large scale expression of isotope-labelled proteins 
 
The expression of isotopically enriched proteins was carried out in M9 medium 
(per litre: 6.0 g Na2HPO4, 3.0 g KH2PO4, 0.5 g NaCl, 1.0 g NH4Cl, sterilised in 
autoclave and supplemented with 2 g Glucose, 1 mL 1 M Thiamine, 1 ml 0.1M 
CaCl2, 2 ml 1 M MgSO4, antibiotics and 10 ml M9 trace elements see Table 2). 
For the expression of protein [15N]-labelled, 15NH4Cl from Cambridge Isotope 
Laboratories was used at 1.0 g/L. In the case of  [13C]-labelled protein, 
uniformly labelled [13C]-Glucose (Cambridge Isotope Laboratories) was used 
at 2.0 g/L. As described above, for unlabelled medium the cells were grown 
until OD600 of 0.6 and then the protein expression was induced using IPTG. 
After 3 hours of expression time the cells were harvested and frozen as 
above. 
 
Purification of proteins 
 
All the cell pellets were resuspended in 30 mL of Nickel buffer A (Table 2) with 
the addition of Lysozime and phenylmethylsulfonyl fluoride (PMSF) in final 
concentration 2.0 mg/ml, used as protease inhibitor. The cells were then 
cracked by sonication (3 minutes with a pulser 5 sec on and 5 sec off at 
amplitude of 30%). The cells lysate was harvested at 1700 rpm for 1 hour. The 
supernatant was then separated from the cells particles and ready for 
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purification. 
Below I report the sequential steps for each purification and the details of the 
columns and buffers used. 
 
Ni-affinity column → TEV Cleavage → Ni-affinity column → Heparin column 
 
Chromatography procedures 
 
Ni-affinity column 
 
A Ni-NTA (nichel-nitilotriacetic acid) resin from Qiagen was used in this project 
for affinity purification of both domains of LARP4  recombinant protein 
expressed with a (His)n tag. 
Superflow resin is capable of binding up to 30 mg of protein. The column was 
equilibrated with 2 column volume (CV) of Ni-column Buffer A (see Table 2), 
then the protein sample was loaded with flow rate of 2 mL/min. Elution of 
bound proteins was obtained using a linear gradient of 20 CV of Ni-column 
Buffer B and was collected in fractions of 3 mL. 
 
TEV Cleavage 
 
The TEV protease is a highly site-specific cysteine protease that is found in the 
Tobacco Etch Virus (TEV). The optimum recognition site for this enzyme is the 
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sequence Glu-Asn-Leu-Tyr-Phe-Gln-Ser and cleavage occurs between the 
Gln and Ser residues. Some of the advantages of this enzyme are its high 
specificity and its high activity rate. One of the main uses of this protein is for 
removing affinity tags from purified proteins. 
To remove the Tag present at the N-terminal of the protein, a TEV Cleavage 
was used. The protein after a Ni-NTA column was dialysed overnight against 
TEV buffer (see Table 2). When the reaction was complete, the solution was 
loaded on a benchtop Ni-affinity column to separate the cleaved protein 
from Tag-TEV (which has His-Tag) and uncleaved product, at the end the 
fractions collected were put overnight against Heparin buffer dialysis.  
 
Heparin column 
 
5 ml HiTrapTM Heparin HP Columns prepacked with Heparin SepharoseTM High 
Performance (Pharmacia) was used for purification of both LARP4s. 
Before the use, the column was equilibrated with 2 CV of Heparin-Buffer A, at 
3 mL/min flow rate. Once the protein was loaded, the elution occurred using 
a linear gradient of a 30 CV Heparin-Buffer B.  
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TABLE 2: List of buffers used during the purification steps performed in this project 
Ni-column A: 50 mM Tris, 10 mM Imidazol, 300 mM NaCl, 5% Glycerol, pH 8.0 
Ni-column B: 50 mM Tris, 500 mM Imidazol, 300 mM NaCl, 5% Glycerol, pH 8.0 
TEV cleavage: 50 mM Tris, 1 mM EDTA, 1 mM DTT, 50 mM NaCl, pH 8.0 
Heparin buffer dialysis: 50 mM Tris, 100 mM KCl, 0,2 mM EDTA, 1 mM  DTT, pH 7.25 
Heparin A: 50 mM Tris, 10% Glycerol, pH 7.25 
HeparinB: 50 mM Tris, 10% Glycerol, 2M KCl,  pH 7.25 
NMR buffer dialysis: 20 mM Tris, 100 mM KCl, 0,2 mM EDTA, 1 mM DTT, pH 7.25 
M9 trace elements: 0.5 g FeCl3, 0.05 g ZnCl2, 0.01 g CuCl2, 0.01 g CoCl2, 0.01 g H3BO3, 
5 g EDTA per 1L 
 
NMR samples preparation 
 
All the NMR samples were prepared at the required concentration by 
centrifugation at 4000 rpm using Vivaspin with a filter cut off 3 kDa, from a 
diluted solution coming from overnight dialysis in NMR buffer. A maximum of 
10% D2O was added to all samples. 
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NMR measurements 
 
All spectra were acquired at 293K on Bruker NMR spectrometers operating at 
a 500 and 700 MHz proton frequency. 
Spectral width of 10 ppm for the 1H and 32ppm for 15N dimensions were used. 
The spectral width of 13C were chosen according to the spectrum 28 ppm for 
the HNCA,1 70 ppm for the CBCA(CO)NH.2,3  
The mixing time for the heteronuclear 3D NOESY experiments was 100 or 120 
ms. Squared shifted sine-bell windows functions were used in all dimensions 
before Fourier transformation. Proton chemical shifts are referred to DSS at 0 
ppm and were calibrated on the water resonance at 4.65 ppm; nitrogen and 
carbon chemical shifts were calculated by indirect referencing.4  
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Results 
 
In my work I carried out structural studies of the two domains of LARP4, 
namely LARP4 (111-196) (corresponding to the La Motif) and LARP4 (196-287) 
(the RRM1). This entails sample preparation followed by acquisition and 
analysis of the NMR experiments. 
 
For LARP4 (111-196) a previous student in the Conte’s lab found the best 
condition to study this domain by NMR, but as part of my work I carried out 
the purification for this domain for NMR studies. I also carried out the NMR 
assignment, the side chain assignment and structural calculation. 
For LARP4 (196-287) domain I found the best condition to obtained a good 
NMR sample and I have done the purification and completed the backbone 
assignment.  
For the La module I have carried out the purification and backbone 
assignment (based on the data found for individual domains). 
In this part of the thesis I describe in detail the application of the NMR 
techniques such as multidimensional heteronuclear experiments, applied in 
combination with routine isotopic enrichment of the protein, which permitted 
the detailed characterisation of the two domains. 
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Purification of LARP4 (111-196) 
 
The LARP4 (111-196) clone used tag containing six histidines at the N-terminal 
end of the protein that allow an easy purification on immobilised metal 
affinity columns. The supernatant, containing tagged LARP4 (111-196) 
obtained after centrifugation at 17000 rpm for 40 minutes, was loaded onto a 
Ni-NTA column from Qiagen equilibrated with the Ni-affinity column buffer A 
(see Table 2 Chapter V). Elution was performed using 250 mM Imidazol with 
linear gradient (figure 5).  
 
Figure 5: Ni-NTA column purification profile for LARP4 (111-196). The protein was loaded on 
the column at 3 mL/min flow rate. After washing out the unbound contaminants (when the 
absorbance went back to the baseline) Imidazol gradient (elution buffer) was started. The 
wide peak eluted is mainly LARP4 (111-196) together with nuclei acids. 
                                       
Flow Through 
                                       
    LARP4 111-196 
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From the chromatogram is clear that the protein is present in the fractions 
between A10 and C6, as confirmed from the previous study made by 
another student; so I have collected and dialysed these fractions against the 
TEV overnight, in order to remove the N-terminal Histidine tag.  
After TEV cleavage, to obtain the protein free from the TEV uncleaved 
products, additional Ni-NTA column was required: LARP4 (111-196) from 
dialysis was loaded onto a bench top Ni-NTA column. 
In figure 6 we can see the cleaved LARP4 (111-196) after purification.  
 
 
Figure 6: SDS PAGE analysis of Ni-NTA column of LARP4 (111-196) following TEV cleavage. Bf 
is the fraction before the TEV cleavage, FT (Flow Through) is the protein that not binds the 
column, WA is the washing of the column with Ni-buffer A and WB is the histidine tag that 
binds the column and is eluted using 100% Ni-buffer B. 
 
By looking at the SDS PAGE it is clear that the protein free from His Tag is in the 
fractions FT and WA, these fractions were pooled and dialysed against 
Heparin buffer dialysis (see Table 2) overnight.  
LARP4 (111-196) from dialysis was loaded on a 5 ml Hi-Trap DEAE 
(diethilaminethil) FF column prepacked with DEAE-Sepharose Fast Flow 
25 
KDa 
 
80 
20 
15 
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M  Bf  FT WA WB 
 
 
Cleaved protein 
Uncleaved protein 
TEV 
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(Pharmacia). Before loading, the column was equilibrated using 2 CV of 
Heparin buffer A at 3 mL/min flow rate. The protein was collected in the FT 
and the column washed using 5 CV 100% Heparin buffer B (figure 7).We used 
the DEAE column in order to remove nucleic acids. 
 
Figure 7: Hi-Trap DEAE purification profile for LARP4 (111-196). This purification step is essential 
to separate the protein from nucleic acids. It is possible to appreciate the separation of 
nucleic acids mainly present in the flow through.  
 
The chromatogram shows that the pure protein is present in the fractions 
between A12 and B10, therefore I collected all the purest fractions and 
dialysed them overnight in NMR buffer pH 7.25; the day after the protein was 
concentrated on Vivaspin with a cut off of 3 kDa. The final concentration was 
then evaluated by UV measurements using an empirical extinction 
Impurities: mainly 
nucleic acids 
                                       
    LARP4 111-196 
 159 
 
coefficient (http://www.expasy.org/tools/protparam.html).  
 
Purification of LARP4 (196-287)  
 
The LARP4 (196-287) clone used tag containing six histidines at the N-terminal 
end of the protein that allows an easy purification on immobilised metal 
affinity columns. The supernatant, containing tagged LARP4 (196-287) 
obtained after centrifugation at 17000 rpm for 40 minutes, was loaded onto a 
Ni-NTA column from Qiagen equilibrated with the Ni-column buffer A (see 
Table 2 Chapter V). Elution was performed using 250 mM Imidazol with linear 
gradient (figure 8).  
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Figure 8: Ni-NTA column purification profile for LARP4 (196-287). The protein was loaded on 
the column at 3 ml/min flow rate. After washing out the unbound contaminants (when the 
absorbance went back to the baseline) Imidazol gradient (elution buffer) was started. The 
wide peak eluted is mainly LARP4 (196-287) together with some impurities and nuclei acids.  
 
Fractions were monitored by SDS PAGE (figure 9) and as shown below my 
protein is present in the fractions between B5 and C9, so I have collected 
and dialysed these fractions against the TEV overnight, in order to remove the 
N-terminal Histidine tag.  
 
 
                                       
                                          His Tag LARP4 196-287                        
            
            Flow Through           
             
 161 
 
 
 
Figure 9: SDS PAGE analysis of Ni-NTA column elution of LARP4 (196-287). The presence of the 
N-teminal Histidine Tag allows an easy purification of the protein. Protein ladder is loaded on 
the left (M), and each subsequent lane is numbered according to the corresponding 
fraction eluted from the Ni-NTA column. His-tagged LARP4 (196-287) migrates at an 
approximate MW of 10 kDa. 
 
After TEV cleavage, to obtain the protein free from the TEV uncleaved 
products, additional Ni-NTA column was required: LARP4 (196-287) from 
dialysis was loaded onto a Ni-NTA column, in figure 10 we can see the 
cleaved LARP4 (196-287) after purification.  
 
Figure 10: SDS PAGE analysis of Ni-NTA column of LARP4 (196-287) following TEV cleavage. Bf 
is the fraction before the TEV cleavage, FT (Flow Through) is the protein that not binds the 
column, WA is the washing of the column with Ni-buffer A and WB is the histidine tag that 
binds the column and is eluted using 100% Ni-buffer B. 
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The SDS PAGE (figure 10) indicated the presence of the free protein from His 
Tag in the fractions FT and WA. These fractions were pooled and dialysed 
against Heparin buffer dialysis (see Table 2) overnight.  
LARP4 (196-287) from dialysis was loaded on a 5 ml Hi-Trap Heparin column 
(Amersham-Pharmacia Biotech) equilibrated in Heparin-column Buffer A and 
eluted using linear gradient of 2 M KCl over 15 CV (figure 11), in order to 
remove nucleic acids. 
 
Figure 11: Hi-Trap Heparin purification profile for LARP4 (196-287). This purification step is 
essential to separate the protein from nucleic acids. It is possible to appreciate the 
separation of nucleic acids mainly present in the flow through.  
 
The figure 12 shows the pure LARP4 (196-287) protein obtained after the 
heparin column step: the purest fractions were pooled together and dialysed 
Impurities: mainly 
nucleic acids 
Impurities 
                                       
    LARP4 196-287 
                                       
        LARP4 196-287 
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overnight in NMR buffer pH 7.25; the day after the protein has been 
concentrate on Vivaspin with a cut off of 3 kDa. The final concentration was 
then evaluated by UV measurements using an empirical extinction 
coefficient (http://www.expasy.org/tools/protparam.html).  
 
Figure 12: SDS PAGE analysis of Heparin column elution of LARP4 (196-287): pure protein is 
obtained after this purification step. Fraction from C12 to D10 were pooled together and 
dialysed overnight in NMR buffer. 
 
While for LARP4 (111-196) a previous student from Conte lab found the best 
condition to prepare a good NMR sample, for LARP4 (196-287) I carried out a 
careful analysis to find the best NMR conditions for structural studies. 
The project started with the analysing NMR data of the longer LARP4 (196-
303) domain at pH 7.25 (previously prepared). However, I found difficulties in 
obtaining complete backbone assignment, in particular the resonance 
corresponding to last part of the domain appeared to be missing. As a result I 
decided to use a shorter clone where the last part, seemingly not folding into 
a secondary structure, was cut. I then started studying the LARP4 (196-287) 
domain obtaining a complete backbone assignment. 
KDa 
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 164 
 
By comparing the 1H NMR of two RRMs it can be seen that there is not a big 
difference between the two domains, therefore I started to study the 
LARP4(196-287) (figure 13). 
 
Figure 13: Comparison of 1H NMR spectra of LARP4 (196-303) (on the top) with LARP4 (196-
287) (on the bottom) at the same condition pH 7.25. 
 
Among the tests carried out to optimise the sample for NMR structural 
determination, I checked the stability of the domain over time and in 
different buffer, temperature and concentration conditions.  
To start with, I took the NMR sample of LARP4 (196-287) at pH 7.25 shown in 
figure 13 and I checked its stability after one week investigating for any 
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changes, but no change was detected as the sample maintained the same 
profile shown before.  
Next, I decided to change the pH, in particular I tested the protein at pH 5. 
The buffer 20 mM Sodium Acetate, 100 mM Sodium Chloride, 0.2 mM EDTA 
and 1 mM DTT, pH 5 was used. 
1H NMR spectra at pH 5 was compared with the same sample at pH 7.25, and 
no great differences could be seen in the 1D experiment (figure not 
reported). I further checked the stability of the protein at pH 5 after several 
weeks and the sample looked stable. 
Further analysis was then conducted with an HSQC experiment of LARP4(196-
287) at pH 5 overlapping it with the HSQC of LARP4 (196-303) at pH 7.25. The 
advantage of the 1H-15N HSQC was much better resolution compared to the 
1D proton spectra, enabling us to see individual resonances. 
Figure 14 shows that some shifts occurred, and this was a predictable 
outcome for having changed the condition of the experiment, but 
interestingly some new peaks seemed to appear. 
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Figure 14: Overlapped of HSQCs spectra of LARP4 (196-303) pH 7.25 (black) and LARP4 (196-
287) pH 5 (red). 
 
It is well known that reducing the concentration of salts in the NMR sample 
will provide a better sensitivity hence allowing the detection of more peaks, 
because this is a better condition for the NMR CryoProbe. For this reason I 
decided to use an NMR buffer at pH 5 but without salts and also in this case 
no changes were found even after some weeks (figure 15). 
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Figure 15: Comparison of 1H NMR spectra of LARP4 (196-287) at pH 5 without salts (on the 
top) and with salts (in the middle) and LARP4 (196-287) at pH 7 (on the bottom).  
 
Nonetheless, when I actually acquired all the NMR spectra of LARP4(196-287) 
at pH 5 without salts I detected a stability problem that was not detected in 
the early preliminary tests. In fact by comparing the previously acquired 
HSQC with the one obtained in the latest experiments, I noticed some 
differences: few peaks moved and others disappeared (figure 16). 
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Figure 16: Overlap of HSQC spectra of LARP4 (196-287) pH 5 without salts. 
 
Following this evidence I decided to compare those 1H-15N HSQC of LARP4 
(196-287) at pH 5 without salts with the HSQC of LARP4(196-287) at pH 5 with 
salts (figure 17); in particular I have overlapped the spectra of a fresh sample 
without salts with the sample at pH 5 with salts, then I have overlapped a 
sample, at pH 5 without salts, acquired after several experiments run at room 
temperature, with the sample at pH 5 with salts.  
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Figure 17: On the top I reported the overlap of HSQC spectra of LARP4 (196-287) pH 5 
without salts before (black) with LARP4 (196-287) pH 5 with salts (red), whilst on the bottom I 
reported the overlap of HSQC spectra of LARP4 (196-287) pH 5 without salts after (black) with 
LARP4 (196-287) pH 5 with salts (red). 
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In this analysis I noticed that some peaks had disappeared in the spectra at 
pH 5 with salts, these are in particular amino acids situated at the end of the 
protein’s primary sequence.  
Having performed all these analysis I drew the following conclusions: 
• to study the LARP4 (196-287) because, in contrast with the longer 
protein LARP4 (196-303), it allows for a complete assignment.  
• to acquire all the spectra needed for the complete NMR domain’s 
assignment , at pH 7.25 which proved to produce very stable results. 
Although at pH 5 we have been able to get a better NMR spectra’s 
resolution whether with salts or without but as a downside we have 
detected a stability problem in the NMR spectra acquisition lasting 
several days during the experiments. 
 
The decision to work at pH 7.25 was also justified by the fact that while 
performing the analysis for different pH conditions, I also prepared a sample 
of LARP4 (111-287), La Module (including both La Motif and RRM domains), 
for crystallographic studies and as is known the best condition for them is to 
work at pH 7.25.  
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NMR analysis of LARP4 (111-196) and (196-287) 
 
To test the suitability of LARP4 (111-196) and (196-287) samples for structural 
determination by NMR spectroscopy an initial [1H-15N] Heteronuclear Single 
Quantum Coherence (HSQC)1 2D experiment was recorded. Figure 18 reports 
the HSQC of the two domains of LARP4; the [1H-15N] HSQC displays cross-
peaks for each proton bound to nitrogen, in particular backbone or side 
chain amide protons: this spectrum is considered the “finger-print” of the 
protein. The dispersion of the cross-peaks indicates that both proteins are 
folded and feasible for NMR analysis. 
The purified samples of [15N] and [15N, 13C] labelled LARP4 (111-196) and 
LARP4 (196-287) were used to record NMR spectra on Bruker spectrometers.  
 
A 
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Figure 18: [1H-15N] HSQC of LARP4 (111-196) (A) and LARP4 (196-287) (B). 
 
Assignment of NMR spectra 
 
In order to solve the structure of a protein by NMR spectroscopy, the first 
stage of the analysis is spectral assignment, in which each signal in the 
spectra has to be associated with a specific nucleus in the molecule. In 
general this process can be divided in two parts, the sequential assignment 
for the nuclei in the protein backbone and the assignment of the nuclei in the 
amino acid side chains. 
The assignment of LARP4 (111-196) and LARP4 (196-287) was achieved by 
employing triple resonance NMR experiments. These experiments are so 
called because three different nuclei (1H, 15N and 13C) are correlated. All 
these experiments rely on the ability to transfer magnetisation between 
B 
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covalently attached nuclei through-bond scalar couplings. The most 
common way to transfer magnetisation between 1H and 15N nuclei or 
between 1H and 13C nuclei is an INEPT (insensitive nuclei enhanced by 
polarisation transfer) sequence.  
The INEPT transfers the magnetisation from the 1H nucleus (I spin) to the 
attached 13C or 15N nucleus (the S spin). After the transfer the S spin nucleus 
can be frequency labelled. At this point the magnetisation can then be 
transferred either to another nucleus or back to the original 1H nucleus for 
detection. All of the triple resonance experiments used for assigning both 
LARP4 domains work on the same basic principles. The first step is to transfer 
the magnetisation from 1H to 15N and then to the other nuclei of interest. 
Figure 19 shows a schematic representation of the magnetisation transfer 
through bounds that occurs in some of the used experiments: the 
nomenclature directly refers to the atoms detected during the acquisition.2 
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Figure 19: Schematic representation of magnetisation transfer occurring in the 3D NMR 
experiments used for the sequential assignment of protein backbone. The nomenclature on 
the right2 indicates the magnetisation transfer pathway and spin that are frequency labelled. 
The magnetisation originates from the amide proton and the arrows indicates the transfer 
direction. 
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1H, 13C and 15N backbone assignment of LARP4 (111-196) and 
LARP4 (196-287) 
 
In the HNCA experiment3 the magnetisation is transferred from amide proton 
(1HN) to the directly attached nitrogen nuclei (15N) through an INEPT 
sequence, in a so called “out-and-back” coherence transfer pathway, 
where the magnetisation is detected on the same spin from which it 
originated. The normal out-and-back type contribution can be written in a 
short notation as:  
 
1HN→15N→13Cα(t1)→15N(t2) →1HN(t3) 
 
where 1HN, 15N and 13Cα stand for the polypeptide backbone amide proton, 
nitrogen and α-carbon nuclei, respectively, and t1, t2 and t3 indicate the 
chemical shift evolution times. In each step, the magnetisation is transferred 
via strong 1J coupling between the nuclei (see Table 3). The nitrogen atom of 
a given amino acid is correlated with both 13Cα, its own and the one of the 
preceding amino acid (i-1). Because the coupling which connects the 
nitrogen atom with the 13Cα carbon of the preceding amino acid (13Cαi-1) (2J 
= 4-7Hz),3 it is sometimes possible to discern the cross signal between intra- 
and inter-residual carbons, due to a different peak intensity. However, this is 
not always clear because geminal coupling constants can vary with the 
dihedral angles; furthermore, spectral overlap often complicates the analysis 
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requiring a second experiments, namely HN(CO)CA, to be used in 
conjunction with HNCA. The HN(CO)CA experiment correlates the backbone 
amide proton and nitrogen (HNi and Ni) to the alpha-carbon of the 
preceding residue (13Cαi-1). The magnetisation transfer between the amide 
nitrogen and the alpha carbon takes place in two steps, via the carbonyl 
carbon (see figure 19): the first step is the transfer from 1HNi to the CO of the 
preceding amino acid, then the magnetisation travel to the 13Cαi-1 and is 
detected. The respective constants coupling are JNCO= 15Hz and JCαCO= 55Hz 
as reported in Table 3. 
 
   1 bond couplings     2 bonds couplings 
1JCH              140Hz 
1JNH        90-100 Hz 
1JNCO            15 Hz 
1JNCα             11Hz 
1JCαCo          55 Hz 
1JCαCα          35 Hz 
 
 
   2JNCβ       9-11 Hz 
   2JNCα         4-7 Hz 
Table 3: The basic coupling constants used to optimise the pulse sequence. Since the 1H-15N 
and 1H-13C one bound coupling constants are comparably large, the 3D heteronuclear 
experiments are highly efficient.  
 
To facilitate the analysis of 3D experiments such as HNCA and HN(CO)CA, 
strips are extracted in correspondence of peaks in the [1H-15N] HSQC 
spectrum and strip plots are made to trace the resonance down the 
backbone of the protein as illustrated in figure 19. Here the strips are placed 
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in a row to show the sequential connectivities from each amino acid to the 
preceding one: the blue line connects the 13Cα of the preceding amino acid 
(i-1) to the subsequent 13Cα (i). As previously explained it is possible to 
appreciate a difference in the cross signal intensities due to the different J-
coupling constants. 
In the CBCA(CO)NH,4,5 the resonances of Cα and Cβ of the preceding i-1 
amino acid are correlated to the HN of the own i amino acid. In the 
HNCACB, both the i-1 and the i Cα and Cβ are correlated to the NHi. In figure 
20 I report the example of HNCA of LARP4 (111-196). 
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Figure 20: Sequentially arranged strips extracted from the HNCA spectrum of [15N-13C]-LARP4 
(111-196). Each 1HN correlates with two peaks, the 13Cαi and the 13Cαi-1. these strips were 
placed in arrow to show the sequential connectivities from each amino acid to the 
preceding one: the i-1 residues are connected to the i residues with a blue line. 
 
Thus for every strip extracted in correspondence of a cross-peak in the [1H-
15N]-HSQC, a spin system consisting of two pairs of carbon resonances are 
known, one relative to the i amino acid the other to the preceding one: this 
allows the determination of a sequence of spin systems in a similar way to 
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that for the analysis of the HNCA/HN(CO)CA experiments. 
The HNCACB/CBCA(CO)NH set provide an additional advantage over the 
HNCA/HN(CO)CA, in that the Cβ chemical shift dispersion is wider than that 
observed for Cα signals. The additional Cβ chemical shift information can 
therefore help to resolve ambiguities in the sequential assignment due to 
overlap of Cα resonances. Furthermore, the Cβ chemical shift are more 
residue-specific than the Cα ones and often can be used to identify the 
amino acid type that corresponds to the peaks in the spectrum. For example, 
characteristic chemical shifts such as the Cβ of alanine, serine and threonine 
can give fundamental clues in the identification of the amino acid type. 
In the HNCO experiment,4,5 the magnetisation is transferred from the amide 
proton to the directly attached 13CO(i-1) carbon atom (figure 20). The HNCO 
also is very useful for resolving accidental signal degeneracy in the HSQC 
projection. In proteins, every amide proton is covalently bonded to a single 
CO group, and therefore we expect to find only one cross signal per 
frequency in the HNCO. Hence, if two cross signals are observed at the 
frequency of an amide proton, this indicate the presence of two amino acids 
with accidentally degenerate amide protons. One limitation of the use of this 
experiment is for the amino acid preceding proline residues: there is no 
magnetisation transfer because the 1HN is not present. 
By analysing all of these spectra described above, an almost complete 
backbone assignment was obtained for the two LARP4’s domains. 
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Secondary structure prediction 
 
The secondary structure prediction of LARP4 (111-196) and (196-287) was 
performed using TALOS software (figure 22).6  
All the collected chemical shift data were used to calculate φ and ψ 
dihedral angles using TALOS, which combined the chemical shift information 
of 1Hα, 13Cα, 13Cβ, 13CO, 15N together with sequence information derived 
from a database of high-resolution NMR and X-ray structures.  
  
Figure 22: Secondary structure prediction of LARP4 (111-196) (A) and LARP4(196-287) (B) 
obtained by TALOS. 
 
TALOS evaluates the similarity in amino acid sequence and secondary 
structure for a string of three sequential amino acids relative to all triplets of 
sequential residues contained in the database. The TALOS output for the φ 
and ψ backbone angles of the central residue in each string consists of the 
average of the corresponding angles in the 10 strings in the database with 
the highest degree of similarity.  
B 
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The program classifies only those predictions for which at least nine out of ten 
predictions fall in the same populated region of the Ramachandran plot.  
TALOS analysis shows that for the domain LARP4 (111-196) we have the same 
organization such as in the La Motif 1-103 of the genuine La protein; whilst for 
LARP4 (196-287) domain we have a difference from the RRM 105-202 of La 
genuine protein, perhaps a small additional strand before strand β3 (figure 
23). 
 
 
 
 
 
 
 Figure 23: Comparison of the TALOS data of the two domains of LARP4 with the two 
domains of La genuine protein. A) Comparison of the La Motif domain of the two different 
proteins. B) comparison of the RRM domain of the two proteins. (In red the α-helix and in blue 
the β-strand). This is the alignment amino acid sequences obtained from TCOFFE.7 
 
 
 
 
 
 
 
A 
B >La 105-202      GRWILKNDVKNRSVYIKGFPTDATLDDIKEWLEDKGQVLNIQMRRTLHKA 
>LARP4 196-287   --------HKRCIVILREIPETTPIEEVKGLFKSENCPKVI----SCEFA 
  
>La 105-20       FKGSIFVVFDSIES---AKKFVETPGQKYKETDLLILFK--DDYFAKKNEERKQNKVE 
>LARP4 196-287   HNSNWYITFQSDTDAQQAFKYLREEVKTFQGKPIMARIKAINTFFAK-NGYR---LMD 
 
 
>La 1-103        MAENGDNEKMAALEAKIC--HQIEYYFGDFNLPRDKFLKEQIKLDEGWVP 
>LARP4 111-196   ------NSAVSTEDLKECLKKQLEFCFSRENLSKDLYLISQMDSDQ-FIP 
 
>La 1-103        LEIMIKFNRLNRLTTDFNVIVEALSKSKAELMEISEDKTKIRRSPSKPLPEVTDE 
>LARP4 111-196   IWTVANMEEIKKLTTDPDLILEVLRSS--PMVQVDEKGEKVRPS----------H 
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1H and 13C side chain assignment of LARP4 (111-196) and 
LARP4 (196-287). 
 
The sequential assignment by triple resonance experiments yields the 
chemical shifts for the backbone atoms, whereas the amino acid side chain 
chemical shifts can be assigned using 13C- edited NOESY in H2O, 13C- edited 
NOESY in D2O and 15N- edited NOESY. 
The combination of these experiments permitted completion and 
confirmation of the assignment of the side chains: for almost all residues a 
complete assignment was obtained, some protons from the aromatic side 
chains (δ, ε and ζ) as well as Hε of some Lysines were not assigned. The 
percentage of assigned carbons is also relatively high, at 85%. 
In figure 24 I report, an example, of the 13C- edited NOESY analysis of Ile154 of 
LARP4 (111-196) side chain. The Cα plane is the starting point: the selected 
diagonal peak (asterisk) is the Hα; in correspondence with this chemical shift it 
is possible to observe the complete pattern of NOE signals to the aminoacid 
side chain. Lines were scanned in order to find similar patterns and the 
simultaneous analysis of the 15N- edited NOESY facilitated the assignment of 
the side chains of the two domains. With this methodology most of the side 
chains were assigned, creating the basis for the collection of NOE-based 
restraints which was performed next. 
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Figure 24: Analysis of the 13C- edited NOESY of LARP4 (111-196) for Ile 154. Strips are 
extracted from the spectrum and placed in a row. Starting from the 13Cα, the side chain 
pattern was recognised and selected. 13C planes were subsequently scanned to find 
comparable patterns that defined the 13C chemical shift of the side chain. The diagonal 
peak (indicated by asterisk) is the directly attached proton. 
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STRUCTURE DETERMINATION 
 
Obtaining a chemical shift assignment is not a goal in itself, and is usually 
used in conjunction with other experiments to obtain a protein structure. In 
principle, all observable NMR, such as NOE, chemical shifts, hydrogen bonds 
and dihedral angles provide information on the protein conformation. 
The three-dimensional structures of the LARP4 La Motif (111-196) and RRM 
(196-287) were determined using the new software UNIO10 with a procedure 
where we have combined automated NOE assignment (CANDID)8, 
automated NOESY peak picking (ATNOS)9 and structure’s determination 
module. 
The input for ATNOS/CANDID consists of: 
• the protein’s amino acid sequence  
• the chemical shift lists from the specific sequence’s resonance 
assignment 
• and one or several 3D NOESY spectra.  
 
ATNOS performs multiple cycles of NOE’s peak identification, it was used in 
concert with the software CANDID to obtain the automated NOE assignment 
while the protein’s structure calculation was identified by the CNC software.  
In the second and subsequent cycles, the intermediate protein’s structures 
are used as an additional guide for the interpretation of the NOESY spectra. 
CANDID includes two new elements making it robust with respect to the 
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presence of artefacts in the input data: network-anchoring and constraint-
combination, which have a key role in the de novo protein’s structure 
determinations for the successful generation of the correct polypeptide fold 
by the first CANDID cycle. 
Network-anchoring is based on the evidence that any network of correct 
NOE cross-peak assignments forms a self-consistent set. 
The initial chemical shift-based assignments for each individual NOE cross-
peak are therefore weighted by the extent to which they can be embedded 
into the network formed by all other NOE cross-peak assignments. 
Constraint-combination reduces the deleterious impact of artefact NOE, 
assigning an upper distance constraints to the input for the protein’s  structure 
calculation by combining the assignments for two or several peaks into a 
single upper limit distance constraint, which lowers the probability that the 
presence of an artefact peak will influence the outcome of the structure’s 
calculation. 
The protocol of ATNOS/CANDID comprised seven iterative cycles of NOESY 
peak picking and NOE cross-peak identification with ATNOS9, automated 
NOE assignment with CANDID8, 3D structure calculation with CNS.  
The second and subsequent cycles differ from the first cycle for the further 
addition of selection criteria targeting the cross-peaks and NOE assignments 
which are based on the assessments of the protein’s structure-guided search 
of the experimental NOESY spectra. 
The increase in the number of NOE cross-peaks identified and of the 
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conformationally meaningful NOE upper distance constraints between the 
first and second cycles, reflects the fact that the regions near the diagonal 
and the solvent line were added for the spectral analysis in cycle 2, and that 
additional protein’s structure-based information was available in cycle 2 to 
guide the analysis of the NOESY spectra.  
These numbers are nearly constant after the second cycle, reflecting that the 
correct protein fold had already been found after the first cycle of 
calculation, whereby the slight decrease of the number of NOE distance 
constraints during the cycle 7 is caused by an additional filtering step 
ensuring that all NOEs have either unique assignments to a single pair of 
hydrogen atoms, or are eliminated from the input for the structure’s 
calculation (figure 25). 
 
Figure 25: Comparison of the structures obtained from the first cycle until the 7th. 
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The output from a ATNOS/CANDID cycle includes: 
• list of NOESY cross-peak assignments 
• list of comments about individual assignment decisions that can 
help to recognize potential artefacts in the input data 
• 3D protein’s structure in the form of a bundle of conformers. 
The results obtained from the Automated Structure Calculation are very 
promising because the comparison of the La Motif structures of genuine La 
protein (obtained with manual method), and the La Motif of LARP4 protein 
(obtained with automatic method), shows that they are very similar. 
The main difference between this two methods is the considerable reduction 
in computation and the related working time.  
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CHAPTER VI 
 
Discussion  
 
Through this research I have started the study of a new component of the La 
related protein (LARPs) big family. 
My protein, LARP4, has the same domain as the Human La genuine protein, 
La Motif and RRM. In contrast with the latter, LARP4 has a new domain PAM2, 
that is involved in the interaction with poly (A) RNA, but it hasn’t got the RRM2 
domain. 
 
Figure 1: Allignment of hLa protein and hLARP4 protein. 
 
LARP4 La motif 
 
From a careful NMR study of LARP4 (111-196) I obtained the structure using a 
new software UNIO-ATNOS/CANDID, with a new approach of automated 
calculation  and I obtained a good superimposition of 20 best structures at 
lower energy. In figure 2 I report the superimposition of these structures and in 
Table 1 I reported the statistics of protein NMR structure determination. 
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Figure 2: Superimposition of 20 best structures at lower energy. 
Table 1: Statistics of protein structure. 
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By overlapping the structure obtained from an automatic calculation 
method LARP4 (111-196) and the structure obtained from a manually method 
La Motif of La genuine protein, it can be shown that we obtained a very 
similar 3D structure (figure 3). 
 
Figure 3: Overlap of the domain La Motif of La genuine protein (green) and LARP4 (blue). 
 
At a first analysis we can see that LARP4 (represented in blue) has some 
regions that are positioned in a different way from La genuine protein, in 
other words some regions of LARP4 are not perfectly aligned with La protein. 
This is not a mistake of assignment because we can still see NOE correlations 
between the amino acid residues involved, and by overlapping the HSQC of 
LARP4 (111-287) La Module, LARP4 (111-196) and LARP4 (196-287) it can 
clearly be seen that all the residues shifted represent the region not aligned 
with La protein (figure 4). 
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Relative orientation of La motif and RRM 
 
As a next analysis I anted to investigate the relative mobility and orientation 
of the La motif and RRM1 in the La Module of LARP4. 
As I describe in chapter three, La genuine protein bind poly (U) RNA with both 
domain: La Motif and RRM1 and only during the interaction the linker that 
connects the two domain fold into an α helix, this folding appears to be an 
indirect effect of RNA binding because there are not contacts between the 
RNA and this part of the polypeptide. Whether this was the case for LARP4 
needed to be investigate. For this I analysed the HSQC of the two individual 
domains compared to the La Module. If the two domains are mainly 
tumbling independently, I would expect very little differences in chemical 
shift compared to the double domain. If on the contrary shifts are seen, this 
might indicate regions of the two domains that interact with each other. 
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Figure 3: Overlap of HSQC of LARP4 (111-287) in green, LARP4 (111-196) in blue and LARP4 
(196-287) in purple. I drew a circle for the residues of LARP4 (111-196) that moved and they 
are involved in a different arrangement structure.  
 
In figure 3 I drew a circle for the residue of LARP4 (111-196) moved with 
respect to the entire domain La Module: the residues involved in the shift are 
the amino acids present on the bottom of the structure. In figure 4 I report the 
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overlap of La motif’s structure of La genuine protein and LARP4 (111-196); in 
red are represented the residues of the La motif that undergo chemical shift 
perturbations in the tandem La Module and therefore probably involved in 
the interaction with the RRM1. By analysing this figure, we can assume that 
the RRM1 could interact with La Motif placed on the bottom of that domain. 
These hypothesis need to be confirmed by further study of the relaxation time 
of the two LARP4’s domains together and separately; such a study could 
clarify whether, like the La genuine protein, the two domains are 
interdependent or not in the La module. 
In my research I have also developed the assignment for LARP4 (111-287), La 
Module, but it proved quite difficult to assign the linker that connect the two 
domain.  
Few explanations can be given which account for the different arrangement 
of LARP4 (111-196) compared with the La genuine protein: 
• probably because in LARP4 we did not have the linker as in La 
genuine protein that fold in α helix 
• or because it is very short  
• or it has a different folding 
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Figure 4: Overlap of the La motif’s structure of La genuine (magenta) LARP4 (grey)  
 
LARP4 RRM1 
 
For LARP4 (196-287) I find the best condition to study the protein and the 
TALOS files show the different prediction at pH 5 or pH 7 (figure 5). 
 
 
 
 
 
 
 
 196 
 
 
 
 
 
 
 
 
 
Figure 5: Comparison of TALOS prediction at different condition: pH5 on the top and pH7 on 
the bottom. 
 
At pH 7 the last α helix reappears, like the one found in the RRM1 of La 
genuine protein. This analysis also indicated that in LARP4 we have either a 
longer β3 strand or a small additional strand preceding β3 (figure 6). 
 
 
 
Figure 6: Allignment of RRM domain of La genuine protein and LARP4 
 
The next step is to pursue structural determination of LARP4 and LARP4-polyA 
RNA complex by NMR and X-ray. 
Additional studies on the NMR data are in progress, in particular the side 
chains assignment of LARP4 (196-287) is almost completed in order to have a 
structure of this domain and to compare it with La genuine protein RRM1. 
>La 105-202      GRWILKNDVKNRSVYIKGFPTDATLDDIKEWLEDKGQVLNIQMRRTLHKA 
>LARP4 196-287   --------HKRCIVILREIPETTPIEEVKGLFKSENCPKVI----SCEFA 
 
>La 105-20       FKGSIFVVFDSIES---AKKFVETPGQKYKETDLLILFK--DDYFAKKNEERKQNKVE 
>LARP4 196-287   HNSNWYITFQSDTDAQQAFKYLREEVKTFQGKPIMARIKAINTFFAK-NGYR---LMD 
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Also in progress are the acquisition of the relaxation time experiments for both 
domains of LARP4 separately (La Motif and RRM) and together (La Module) 
and then with the poly-A RNA. This experiments are very important because 
will allow us to understand which domain and in particular which residues are 
involved in the interaction with the RNA, so that it will be possible to find the 
difference with the La genuine protein.  
We are also planning an NMR and ITC titration of LARP4 (111-287) with poly-A 
RNA to compare all the results against each other.  
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CONCLUSION 
 
At this stage my research can only report the structure of LARP4 (111-196) with 
the important finding that it does not show differences with the same domain 
in La protein, if we exclude the region that is very liked involved in the 
interaction with the RRM1, but this hypothesis need to be confirmed by further 
experiments. 
The most interesting outcome of my research is that this structure has been 
obtained with automatic method which represent an important step forward 
in the calculations domain, having achieved the same results that in the past 
Alfano et al. had reached applying a manual method.  
 
 
